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Structured Abstract 
 
Aims 
To determine the level of demineralisation or remineralisation of sub-surface carious lesions placed 
in situ on an orthodontic appliance and treated with fluoride toothpaste (1450ppm) or a 
combination of fluoride toothpaste (1450ppm) and GC Tooth Mousse™ (CPP-ACP). 
 
Objectives 
To assess the degree of change in mineralisation of subsurface lesions following the application of 
fluoride toothpaste (1450ppm)  and GC Tooth Mousse™(CPP-ACP) with Transverse Microradiography 
(TMR) as volume mineral loss (ΔZ),  lesion depth and lesion width. 
Null Hypothesis 
There is no difference between the remineralising potential abilities of GC Tooth Mousse™ and 
fluoride toothpaste in orthodontic patients.  
 
Design 
A randomised cross-over in situ study, involving the use of prepared enamel subsurface lesions of 
previously extracted premolar teeth being placed intra-orally. The interventions of fluoridated 
toothpaste and fluoridated toothpaste in combination with GC Tooth Mousse™ were given to the 
orthodontic participants in a randomised order with a mid-treatment wash out phase. 
 
Setting 
Department of Health Services Research and the Orthodontic Clinic Liverpool University Dental 
Hospital (LUDH). 
 
Ethical Approval 
Ethical approval was obtained from the National Research Ethics Service (NRES) and the NHS 
Research and Development Offices. This study was given the REC reference number: 13/NW/0742.  
The trial was also registered on Current Control Trials http://www.controlled-
trials.com/ISRCTN04899524/ 
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Sample Size 
The primary outcome variable was percentage mineral Loss ΔZ, calculated by dividing the sample 
value by the control value, and multiplying by 100. Data were used from a previous study 
(Bryniarska, 2012) using the Transverse Microradiography (TMR) technique.  A total of 12 
participants would allow detection between groups of 28% ΔZ with 80% power, at the 5% 
confidence level. 
 
Participant selection 
Inclusion criteria 
 Between the ages of 12 to 17 years 
 Adequate space in the lower premolar region to allow placement of the enamel carrier  
 In a suitably rigid archwire to allow placement of the carrier 
 In good general health and oral health 
 
Exclusion Criteria 
 Allergic to milk products  
 Taking or have taken antibiotics in the last 2 months 
 Unable to maintain adequate oral hygiene 
 
Randomisation 
Each eligible participant was allocated a subject number as they were recruited to the study. 
Intervention order was randomised by a statistician who was not involved in the recruitment process 
using simple computer generated random allocation. The participants were randomly allocated to 
one of two possible orders of intervention; AB or BA. 
 
Method 
The study consisted of 4 distinct 4-week phases.  
 Phase 1   -   Pre-trial wash out  
 Phase 2   -   1st Intervention  (A or B) 
 Phase 3  -    Mid-treatment wash out 
 Phase 4   -    2nd Intervention (A or B) 
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All participants were provided with standard fluoride toothpaste and a toothbrush, and asked to 
brush their teeth for two minutes twice a day with a pea sized amount for the 4-week phase. 
Intervention B participants were also provided with GC Tooth Mousse™ and advised to apply directly 
to the teeth for 5 minutes. The participants were asked not to use any other toothpaste or mouth 
rinses during this trial. The instructions were provided in written form (Appendix 1a, 1b). 
 
Interventions 
Each participant received the pastes in random order:  AB or BA 
A. Standard fluoride toothpaste (1450ppm) 
B. Standard fluoride toothpaste (1450ppm) and topically applied Tooth Mousse™ (GC 
Corporation, Europe) to be applied directly to the teeth 
 
Blinding 
All tubes provided to the participants were covered in insulation tape so the participant was 
unaware of the paste being used. Once the enamel samples were removed from the carrier 
following the in situ phase, samples were recoded by a research technician not involved in the 
clinical study. The samples were then sectioned and analysed so the principle investigator was 
blinded to the participant and intervention during analysis therefore reducing bias. Following TMR 
analysis the coding was revealed. 
 
Samples 
Demineralised enamel samples were created in vitro from human premolar teeth. Samples were 
sectioned, sterilised and placed in a carrier, which was then attached to the orthodontic archwire. 
The carrier consisted of a custom made stainless steel attachment which was a modified version of a 
carrier used in previous clinical studies (Benson, 2000; Bryniarska, 2012). Base-line TMR analysis was 
carried out to allow for a comparison of mineral change following the in situ phase of the trial.  
 
Outcome measures 
The degree of change in mineralisation of subsurface lesions was assessed from mineral content 
profiles using Transverse Microradiography (TMR) following the application of fluoride toothpaste 
(1450ppm) and GC Tooth Mousse™. Three parameters were used; mineral loss ΔZ (vol%μm), lesion 
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depth Ld (μm) and lesion width Lw (μm). This data were then normalised and a percentage change in 
mineral loss, lesion depth and lesion width was calculated (Strang et al, 1987). 
 
Statistical analysis 
The data from TMR analyses was entered into the Statistical Package for Social Sciences (IBM SPSS 
Statistics v22.0). Descriptive statistics calculations carried out included mean, standard deviation, 
and percentage mineral loss. Hypothesis testing was carried out using analysis of covariance 
(ANCOVA), adjusting for the baseline measurements, participant effect and for the order in which 
the treatments were received. A Pearson correlation coefficient was used to compare the quantity 
of Tooth Mousse™ used and the resulting change in mineralisation. 
 
Results 
1. 3 samples (12%) were lost during the in situ phase or damaged during polishing. 
 
2. TMR analysis showed significant remineralisation in both treatment groups compared with 
baselines, as demonstrated by reductions in mineral Loss ΔZ, lesion depth and lesion width.   
 
3. Mineral loss ΔZ reduced by 15.4% and 24.6% for fluoride and CPP-ACP groups respectively, with 
a statistical significant difference between these groups (p=0.023). There was no significant 
effect for the order in which they received the intervention (p=0.760), participant effect 
(p=0.138) or for baseline mineral loss (p=0.505). There was no correlation between the amount 
of mineral loss and the amount of Tooth Mousse™ used  (r =  -0.488, p=0.152). 
 
4.  Lesion depth reduced by 1.6% and 11.1% for fluoride and CPP-ACP groups respectively, with a 
statistically significant difference between these groups (p=0.037). There was no significant 
effect for the order in which they received the intervention (p=0.202), participant effect 
(p=0.970) or for baseline mineral loss (p=0.125). There was no correlation between lesion depth 
and the amount of Tooth Mousse™ used (r =  0.013, p=0.973). 
 
5. Lesion width reduced by 4.5% and 15.3% for fluoride and CPP-ACP groups respectively, with a 
statistically significant difference between these groups (p=0.015). There was a statistically 
significant effect for the order in which they received the intervention (p=0.033). There was no 
significant effect for baseline lesion width (p=0.155) or participant effect (p=0.947). There was 
no correlation between lesion width and the amount of Tooth Mousse™ used (r=0.306,  
p=0.389). 
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Conclusion 
In this study, the null hypothesis that there was no difference between the remineralising potential 
abilities of GC Tooth Mousse™ and fluoride toothpastes was rejected. Despite a wide range in intra-
subject and inter-subject data, an overall trend of remineralisation was observed in both treatment 
groups as demonstrated by reduction in mineral loss ΔZ, reduction in lesion depth (Ld) and reduction 
in lesion width (Lw).  All baseline lesions, on average remineralised during the in situ phase 
regardless of treatment group allocation, however the fluoride toothpaste combined with GC Tooth 
Mousse™ (CPP-ACP) group demonstrated an increased remineralising effect with respect to all 3 
parameters. A statistically significant reduction in mineral loss ΔZ (p=0.023), lesion depth (p=0.037) 
and lesion width (p=0.015) was observed in the fluoride toothpaste combined with CPP-ACP group 
compared to the fluoride toothpaste alone. 
 
Results suggest that the application of GC Tooth Mousse™ in addition to regular fluoride paste does 
have an increasing remineralisation effect on subsurface enamel lesions in orthodontic patients.  
 
Implications 
Enamel demineralisation is a common adverse side effect of orthodontic treatment. The use of 
toothpastes containing CPP-ACP such as GC Tooth Mousse™ has been shown to reduce this 
demineralisation process and promote remineralisation. CPP-ACP pastes in combination with regular 
fluoride toothpaste should be recommended for patients undergoing orthodontic treatment who 
are at high risk of demineralisation or who have demonstrated early signs of white spot lesion 
formation. CPP-ACP paste may also be useful for patients after fixed appliances to promote 
remineralisation of areas where orthodontic demineralisation is evident. 
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1.0 Background & Rational 
1.1 Dental Caries 
Definition  
Dental caries is the process of localised chemical dissolution affecting hard dental tissue due to 
metabolic events taking place within the surrounding biofilm. Organic acid production from bacterial 
fermentation of dietary sugars results in a shift in the dynamic balance of demineralisation-
remineralisation with a net loss of tooth substance. This complex process is directly affected by the 
presence of microbial species, fermentable carbohydrates, fluoride ions, saliva composition and flow 
rate, buffering capacity and time (Figure 1.1.1). Other contributory secondary factors include 
education, social class, attitudes and behaviour (Kidd, 2005). 
 
Figure 1.1.1 Factors affecting the carious process (Modified Keyes and Jordan 1963) 
 
 
Aetiology of caries 
The dental caries process can develop at any tooth site provided the formation and maintenance of 
a biofilm is achieved. Oral sites which are protected from mechanical cleaning and debris removal 
are more likely to develop a mature biofilm. Sites such as pits and fissures on occlusal surfaces, and 
approximal surfaces cervical to contact points are therefore susceptible to stagnation of biofilm and 
the possibility of localised chemical dissolution. It is within this prerequisite biofilm that the 
imbalance of tooth mineralisation occurs due to metabolic events and pH fluctuations as a result of 
microbial activity. This metabolism is dramatically affected by the presence of fermentable 
carbohydrates (Arens, 1998). 
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Dental enamel is highly mineralised and acellular with 99% of its dry weight composed of calcium 
phosphate crystals, and at pH 7.4 hydroxyapatite is the most common form [Ca₅(PO₄)₃(OH)]. In 
normal physiological conditions saliva and oral fluids are supersatured in hydroxyapatite and 
fluorapatite. This results in mineral deposition on porous areas of teeth seen in developmental 
enamel maturation and in the remineralisation of carious lesions. This can also give rise to 
fluorohydroxyapatite and hydroxyapatite formation in calculus deposition. Post dental eruption, 
tooth surface apatite is continually exposed to chemical modification. A dynamic equilibrium 
between dissolution and deposition of minerals within the biofilm fluid occurs (Fejerskov and Kidd, 
2008). 
 
When pH decreases, the solubility of mineral apatite increases rapidly, with a 10 fold increase in 
solubility with 1 unit pH reduction (Larson, 1986  Figure 1.1.2). This acid exposure can result in either 
formation of a carious lesion or an erosion lesion. In pH range 4.0-5.5 the caries lesion develops. This 
is characterised by partial dissolution of tissue leaving a 20-50 µm intact mineralised outer layer, 
with a sub-surface demineralised body of the lesion.  At this pH range, the oral fluids are 
undersaturated with respect to hydroxyapatite but remain supersaturated with respect to 
fluorhydroxyapatite. Therefore subsurface hydroxyapatite is dissolved while fluorhydroxyapatite is 
formed on the enamel surface layer. It is this fluorhydroxyapatite supersaturation and deposition 
that maintains the surface layer integrity.  In the presence of supersaturated hydroxyapatite and 
fluorapatite, partially demineralised apatite crystals can remineralise to their original size, and new 
crystal formation is possible. Although the intact partially demineralised surface layer is accessible to 
remineralisation, this is not normally possible in the sub surface body lesion due to slower diffusion. 
The extent of remineralisation is dependent on the presence of fluoride ions, the buffering capacity 
of saliva and a pH above the critical value. In pH range 2.5-4 oral fluids are undersaturated in both 
hydroxyapatite and fluorhydroxyapatite, and as a result an erosive lesion develops. This is 
characterised by complete demineralisation and dissolution of the outer layer, with the underlying 
remaining enamel unchanged. Once this has occurred remineralisation or replacement of the outer 
enamel layer is not possible (Silverstone, 1973). 
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Figure 1.1.2  Curve demonstarting the rapid increase in solubility as pH decresaes (Larson, 1986) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Early Carious Lesion 
Early enamel caries lesions are characterised by an intact outer mineral layer with subsurface 
mineral loss.  Although at early stages no macroscopic features are present, microscopically inter-
crystalline spaces widen and partial dissolution of the outer enamel surface occurs.  A slight increase 
in enamel porosity is detected at this stage. Lesion progression is associated with increasing inter-
crystalline space enlargement and surface porosity. With continued removal of deep subsurface 
tissue and increasing porosity, a subsurface lesion is formed which is clinically detected as an enamel 
white spot lesion (Silverstone, 1973). 
 
Histologically this is a wedge shaped lesion with the wider base at the outer enamel surface and the 
narrow apex toward the amelodentinal junction (Figure 1.1.3).  The subsurface lesion can be divided 
into 4 zones. The surface zone is the intact enamel outer layer, which is well mineralised and is 
approximately 20-50 µm thick. Below is the body of lesion which is the area of greatest 
demineralisation with a pore volume of 5% near the periphery and 25% in the centre. This layer 
makes up the bulk of the lesion. The dark zone is the advancing front of the lesion. It lies deep to the 
body of the lesion and has a pore volume 2-4% with a reduced level of demineralisation in 
comparison to the body of lesion. The translucent zone is the deepest layer which is unrecognisable 
clinically or radiographically and may vary from 5-100 µm in width. It has a slightly increased porosity 
compared to normal enamel (Fejerskov and Kidd, 2008). 
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Figure 1.1.3 Polarised light microscopy  of an early enamel lesion (Jensen et al , 2000) 
 
1. Surface zone   
2. Body of lesion  
3. Dark zone  
4. Translucent zone  
 
 
 
 
 
 
 
At this stage the white spot lesion is partially reversible and the imbalance between 
demineralisation and remineralisation can be shifted in favour of mineral deposition. This requires a 
supersaturated apatite environment, regular fluoride exposure, diet modification and adequate 
plaque control. Although remineralisation of the outer surface layer is achievable, remineralisation 
of the body lesion is rarely possible (Silverstone, 1973). 
 
Carious Lesion Progression 
Further demineralisation results in progressive advancement of the lesion towards the 
amelodentinal junction. The first sign of dentine reaction to the enamel lesion is tubular sclerosis at 
the deepest aspect of the advancing lesion. When the enamel lesion contacts the amelodentinal 
junction, tubular sclerosis is seen laterally along the junction. Despite previous conventional theories 
this is unlikely to be lateral spread of dentinal demineralisation and destruction, but merely a 
pulpodentinal reaction to stimuli (Fejerskov and Kidd, 2008).           
 
As the enamel crystallites progressively dissolve, eventually the outer surface disintegrates and a 
cavitation is macroscopically present (Figure 1.1.4).  At this point the lesion is irreversible. Rapid 
bacterial invasion occurs with destruction of organic matrix by proteolysis within the most superficial 
dentine (zone of destruction).  Tubular bacterial invasion occurs beneath this zone. As a protective 
measure by the dentinal tubules, fatty degeneration of the tome’s fibres and dentinal sclerosis 
occurs in an attempt to seal off the tubules. In spite of theses attempts the caries process and 
destruction continues. Behind this sclerotic layer a narrow zone of decalcification is seen. Initially the 
tubules have minimal bacterial invasion. With continual decalcification, tubules coalesce and 
 1  2  3  4 
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degrade forming an area of necrotic dentinal debris (Miller's liquefaction foci). Further progression 
of the carious lesion results in pulpal exposure and subsequent pulpitis (Soames & Southam, 2008). 
 
Figure 1.1.4 Illustration of lesion progression stages  
 
1. Reactive Dentin    
2. Sclerotic reaction of translucent zone   
3. Demineralisation zone  
4. Zone of destruction and bacterial invasion  
5. Carious dissolution following peripheral rod direction  
 
 
 
 
 
 
Saliva and buffering capacity 
The oral environment is continually bathed in saliva. Salivary flow produces effective mechanical 
cleaning and oral clearance therefore reducing sugar and acid accumulation in the mouth. However 
saliva’s buffering bicarbonate effect also plays an essential protective role. Salivary components; 
calcium and phospate ions, ensures a supersaturation with respect to hydroxyapatite and offers a 
protective and reparative environment for the teeth.  Calcium and phosphate are present in saliva in 
a number of different forms. They can be in either its ionised or non-ionised form, or firmly bound to 
proteins. Non-ionised calcium increases when salivary pH increases as a result of increased saliva 
flow (Fejerskov and Kidd 2008). In contrast the total phosphate concentration decreases 
dramatically when salivary pH increases as a result of increased saliva flow. 
 
At pH 5.5 (Critical pH) the ion activity product is equal to the solubility product of hydroxyapatite 
resulting in a saturated solution, and consequently a balance between remineralisation and 
demineralisation. However this is a dynamic process. The main determinates of critical pH are the 
total calcium and phosphate concentrations in the saliva. As this is influenced by salivary flow rates, 
the critical pH can vary between stimulated and un-stimulated saliva (Fejerskov and Kidd 2008). 
Antimicrobial salivary constituents include lactoperoxidase, and lysozyme which damage bacterial 
cell walls and lactoferrin which inhibits bacterial aggregation (Kidd, 2005). 
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The role of Carbohydrates  
There is reliable and conclusive evidence that both the total consumption and frequency of dietary 
carbohydrate intake is a major cariogenic risk factor. Carbohydrates provide not only the retentive 
features necessary for bacterial aggregation and colonisation but also act as a substrate for the 
production of acids.  Both the frequency and the duration of carbohydrate consumption are 
influential factors in this demineralization process (Arens, 1998). 
 
Monosaccharides and disaccharides are small molecular weight carbohydrates, commonly known as 
sugars. Monosaccharaides such as glucose, fructose and galactose and disaccharides such as 
sucrose, lactose and maltose are highly cariogenic as they are easily metabolised by bacteria. 
Complex carbohydrates (starches) are less easily metabolised and have a reduced cariogenic effect. 
Naturally incorporated intrinsic sugars or milk product sugars are shown to have no adverse effects 
on dental health (Lingstrom et al 2000, Sheiham 2001). 
 
Sucrose consumption results in a rapid pH reduction below the critical pH within 2-3 minutes (Fig 
1.1.5). However it takes the following 40 minutes for the pH to rises gradually and returns to normal. 
Therefore increased frequency of dietary sugars (especially within 40 minutes) will maintain a 
reduced pH and a cariogenic environment. 
 
Figure 1.1.5   Stephan curve  following sucrose exposure (Modified Stephan and Miller 1943)
 
 
Both national and international data have demonstrated a highly significant and strong positive 
linear correlation between total sugar consumption and caries level (Sreebny, 1982; Miyazaki and 
Morimoto 1996; COMA report 1989). It has been suggested that 50g of sugar is the maximum daily 
“safe” limit without increasing caries risk significantly. Similar results have been found in other 
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studies with a 60g maximum daily limit suggested (Sheiham, 2001).  A highly significant and strong 
positive linear correlation between the frequency of sucrose consumption and caries level has also 
been clearly demonstrated (Rugg-Gunn, 1993). It has been suggested that a threshold of 4 sugar 
intakes per day or 3 between meal sugar snacks demonstrated a marked increase in caries activity 
(Holbrook, 1995). 
 
Although cariology studies clearly demonstrate the association with sugar consumption, it is the low 
pH environment indirectly generated from dietary sugar consumption which has the more important 
role in caries development, not the sugar consumption itself (Marsh, 1998). 
 
Microbial species 
The microbiology of caries is influenced predominately by the role of mutans streptococci within the 
plaque biofilm, although Lactobacilli and sobrinus streptococci also play a contributing role (Marsh, 
1998). Dietary sugars facilitate the production of insoluble plaque matrix polymers by mutans 
streptococci and sobrinus streptococci, which aid initial colonization and retention. The growth of 
these organisms is dependent on the presence of fermentable monosaccharides and disaccharides 
which is provided mainly by sucrose and glucose. As mutans streptococci are well adapted to low pH 
conditions, selective pressures caused by acidic conditions causes mutans streptococci populations 
to thrive. Excessive monosaccharides derived from sucrose exposure are metabolised to promote 
their rapid growth. The result is establishment of mutans streptococci colonies on the tooth surface 
which rapidly metabolise dietary sugars and produce acidic local conditions (Marsh, 1998). Acid 
production is then rapid, with a minimum pH within 5-10 min after exposure to sugar. As a result of 
pH falling below the critical level pH 5.5, net loss in surface mineral occurs. 
 
Pellicle layer and biofilm formation 
A biofilm is a natural physiological process in which microbial communities colonise, multiply and 
aggregate with further bacterial species and subsequently embed themselves in a matrix of 
extracellular polymers. The formation of a pellicle layer is the first stage of biofilm development and 
therefore an essential pre-requisite for the caries process. 
 
The pellicle layer is a thin bacteria free protein film which forms on tooth surfaces rapidly after 
mechanical cleaning. Due to its selectively permeable membrane it has an important influence on 
ion diffusion and therefore influences the demineralisation and remineralisation process. This 
pellicle layer becomes highly saturated with calcium and phosphate and therefore can act as a 
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reservoir for remineralisation and inhibit demineralisation (Hay, 1984). Initial microbial colonisation 
is by bacterial cocci, usually streptococci however as colonisation and development occurs 
actinomyces species predominate (Law, 2007). The ecological plaque hypothesis suggests that 
cariogenic bacteria (such as mutans streptococci) colonise not only diseased oral sites but also 
healthy sites. At diseased sites, however the balance is shifted in favour of cariogenic bacteria due to 
altered environmental conditions (Samaranayake, 2005). 
 
Demineralisation in Orthodontic patients 
Demineralisation of enamel adjacent to orthodontic brackets is a widely acknowledged risk of 
orthodontic treatment. Patients and parents can be disappointed and upset with the appearance of 
enamel demineralisation following removal of fixed appliances (Benson et al, 2004).  The prevalence 
of enamel demineralisation has been reported as high as 50- 96% of patients (Gorelick et al, 1982; 
Mitchell, 1992). The most commonly affected areas are the labial surfaces of the maxillary incisors, 
with the lateral incisor being 3 times more frequently affected than the central incisor (Gorelick et al, 
1982). Remineralisation of these lesions is normally expected to occur post debond provided a 
suitable environment, however Mattousch et al (2007) suggest that adequate remineralisation 
following fixed appliance removal does not always occur, as demonstrated by the fact that 
orthodontic participants have a significantly higher incidence of white spot lesions than those who 
did not undergo orthodontic treatment even 5 years after treatment (Ogaard, 1989). Severe white 
spot lesions may develop frank cavitation of the enamel surface (Figure 1.1.6) and therefore require 
restorative intervention  (Chang et al, 1997).  
 
This demineralisation process is identical to that of non-orthodontic patients and initially manifests 
clinically as a white spot lesion due to subsurface tissue loss and increased porosity. However 
Øgaard and Ten Bosch (1994) suggested that orthodontic white spot lesions may develop and 
progress more rapidly than conventional smooth surface lesions. 
 
The use of thorough tooth drying allows for early and improved detection of white spot lesions 
(Gorelick et al, 1982), and after 14 days of undisturbed plaque accumulation enamel changes can be 
visible. After 3 to 4 weeks, clinical changes can be seen without air drying due to an increased 
porosity of the outer surface (Fejerskov and Kidd, 2008). The increased susceptibility of enamel to 
decalcification during orthodontic treatment is due to the irregular surfaces of brackets, bands and 
wires which increase plaque accumulation and retention. Thorough oral hygiene instruction and 
dietary analysis and advice are essential to reduce this risk.  
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Figure 1.1.6 showing severe demineralisation with cavitation (Lovrov, 2007) 
  
 
White Spot Lesion (WSL) classification 
The severity of white-spot lesions can be quantified according to the International Caries Detection 
and Assessment System II criteria (Pitts, 2004 Figure 1.7). This system was developed to standardise 
caries quantification in order to allow better comparison among cariology studies. 
 
Fig 1.7  International Caries Detection and Assessment System II (ICDAS II) 
Code Description 
0 Sound 
1 First visual change in enamel (seen only after prolonged air drying) 
2 Distinct visual change in enamel 
3 Localized enamel breakdown (without clinical visual signs of dentinal involvement) 
4 Underlying dark shadow from dentin 
5 Distinct cavity with visible dentin 
6 Extensive distinct cavity with visible dentin 
 
 
 
Prevention Program 
A fundamental role of the dental team is to provide dietary and nutritional advice, as diet is an 
inextricable factor in oral health and general wellbeing. The information provided by dental 
professionals should be in accordance with general nutritional recommendations for good health. A 
six step model for the provision of effective dietary counselling was outlined by Rugg-Gunn and 
Nunn (1999).  
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1.2 Caries Prevention 
Chlorhexidine 
Chlorhexidine (CHX) has been studied for over 30 years as an antimicrobial agent that controls 
plaque formation and therefore may prevent caries. Chlorhexidine acts bacteriostatically and covers 
both Gram-negative and Gram-positive bacteria. The efficacy of chlorhexidine is related to its 
concentration and the frequency of application (Baca and Junco, 2003).  
 
The most common applications of chlorhexidine are mouth rinses, sprays, gels and varnishes. 
Chlorhexidine varnishes are the most effective at inhibiting mutans streptococci, followed by gels 
and then mouthwashes (Emilson 1994, Law and Seow 2007). Chlorhexidine mouth rinse has 
demonstrated efficacy in reducing plaque and gingivitis, as well as in decreasing the microbial load in 
saliva and the gingival sulcus (Escribano et al, 2010).   
 
Clinical trials have demonstrated that chlorhexidine varnish and gels result in a clinically significant 
reduction in caries of up to 40% (Banting et al, 2002, Huizinga et al, 1990). The addition of fluoride 
varnish in combination with chlorhexidine varnish has been shown to be a useful, simple, quick and 
non-invasive method for the control and management of existing root caries lesions (Brailsford et al, 
2002). However this has been contradicted by Edwards (2009) who concluded that regular 
chlorhexidine application does not have a substantial effect on the preservation of sound tooth 
structure. 
 
 A systematic review (Slot et al, 2011) concluded that in the absence of professional cleaning and 
oral hygiene instruction, chlorhexidine varnish may provide a beneficial effect in patients in need of 
special care. However the strength of this recommendation was graded as weak. 
 
Ozone 
Ozone (O3) is a powerful oxidising agent which neutralises acids and also disrupts the cell wall of 
microorganisms (Bocci, 1993). Baysan et al (2000, 2004) reported ozone application for 10-20 
seconds was effective in killing 99% of microorganisms in carious lesions, and was also effective in 
reducing mutans streptococci levels in vitro. However more recent in vitro testing showed that 
ozone had no effect on remineralisation of carious lesions (Zaura et al, 2007). While laboratory 
studies suggest promising potential for ozone in dentistry, this has not been shown in clinical studies 
(Rickard, 2004). Ozone should not be considered an alternative to current treatment methods in 
dental practices (Rickard, 2004). More high quality blinded randomised clinical trials are required to 
evaluate the possible use of ozone as a treatment modality in dentistry (Azarpazhooh and Limeback, 
2008). 
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1.3 Caries Remineralisation with Fluoride 
Non-cavitated carious White Spot Lesions (WSL) can be identified at different developmental stages. 
When lesions are detected and contained early, interceptive treatment may reduce the need for 
invasive treatment. Both topical fluoride and Casein phosphopeptide-amorphous calcium phosphate 
(CPP-ACP) have been widely studied to investigate their effectiveness in the remineralisation of 
enamel subsurface lesions.  
 
Fluoride has an essential role in dental caries prevention and enamel remineralisation. Fluoride is a 
natural trace element which is present in certain foods and in many water supplies. Fluoridated 
water at 1ppm concentration provides both a systemic and topical effect and can reduce caries by 
50% (Arnold, 1957).  
 
Pre-eruptive effects of fluoride are due to its incorporation into the enamel crystal lattice structure 
resulting in formation of fluorapatite which has a larger crystal size and improved stability. 
Fluorapatite has a critical ph 3.5, making it less soluble in comparison to hydroxyapatite. Fluoride 
incorporation also affects crown morphology by reducing pits and fissures depth and therefore 
reducing plaque stagnation (Welbury et al, 2005). Post-eruptive effects result in an increased 
remineralisation of porous and demineralised enamel areas. Fluoride ions are absorbed on to the 
tooth surface which attracts calcium and phosphate ions required for new mineral deposition. 
 
Fluoride also has a local antibacterial effect on dental plaque bacteria by blocking the enzyme 
enolase necessary for gycolysis.  Bradshaw et al (1990) reported that mutans streptococci become 
increasingly sensitive to fluoride ions as the pH falls.  Therefore it is suggested that routine topical 
application of fluoride may partially inhibit the metabolism of cariogenic bacteria. 
 
The topical intra-oral effect of fluoride in caries prevention is most beneficial at a constant or high 
frequency low concentration dose as opposed to an irregular high concentration dose (Ogaard, 
1990). Therefore the goal of community based public health programmes should be to implement 
the most appropriate method of maintaining a constant low level of intra-oral fluoride exposure 
(Peterson, 2003). 
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Fluoride Toothpaste 
The regular use of fluoridated toothpaste has been shown to result in a 25% reduction in caries, 
compared with non-fluoridated toothpastes (Marinho et al, 2003). Brushing twice a day with fluoride 
toothpaste compared to once a day has been reported to reduce caries incidence by 20-30% 
(Chesters et al, 1992). The recommended amount of fluoride in toothpaste for adults and 
adolescents is 1400ppm (Welbury, 2005). High fluoride dentifrices have been shown to be 
particularly effective in remineralisation of root caries lesions, due to the increased fluoride 
requirement for root remineralisation compared with enamel remineralisation (Lynch and Baysan, 
2001). A recent randomised controlled trial evaluated the effectiveness of high fluoride  toothpaste 
(5000 ppm) compared with regular concentration fluoride toothpaste (1450ppm) in reducing white 
spot lesions formation during orthodontic treatment. They concluded that there was a statistically 
significant benefit of using high fluoride toothpaste resulting in a relative risk reduction of 31% 
(Sonesson et al, 2014).  
 
Walsh (2010) suggested the benefits of using fluoride toothpaste in preventing caries in children was 
only significant for fluoride concentrations of 1000 ppm and above. This relative caries preventive 
effect increases with higher fluoride concentrations.  For children under 6 years deciding what 
fluoride levels to use should be balanced with the risk of fluorosis (Wong, 2010). 
 
Fluoride Varnish 
Topical fluoride varnish has been shown in randomised controlled trials to have a statistically 
significant effective on remineralisation of incipient carious lesions (Autio-Gold, 2001; Fure and 
Lingström, 2009). Over a 4 year period, fluoride varnish application twice a year resulted in a 40% 
reduction in caries (Zimmer, 1999). Marinho et al (2013) in a review of the literature concluded that 
fluoride varnish gel, resulted in a substantial caries reducing effect of approximately 30-40% DMFT. 
It is generally accepted that for maximum efficiency, fluoride varnish should be applied at least every 
six months (Weintraub et al, 2006). A placebo double blind RCT (Stecksén-Blicks et al, 2007) assessed 
the effectiveness of fluoride varnish (0.1% F) application in preventing white spot lesion formation 
during orthodontic treatment. They concluded that application every 6 weeks resulted in a 70% 
reduction of white spot lesions formation. 
 
An updated Cochrane review (Benson et al, 2013) established that there is some moderate evidence 
that fluoride varnish applied every six weeks was effective in reducing demineralised white spot 
lesion formation in orthodontic patients. But that further adequately powered, double-blind, 
randomised controlled trials are required to determine the best means of preventing demineralised 
white spot lesions in patients undergoing orthodontic treatment. 
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Fluoride Mouthwash 
A review of the literature suggested that fluoride mouthwash is effective in caries remineralisation 
with a DMFT reduction of approximately 25% in children (Marinho et al, 2003). A Cochrane review 
(Benson et al, 2004) recommended the daily use of 0.05% Fluoride mouth rinse for all patients 
undergoing orthodontic treatment, although this was based on weak evidence. 
 
Extensive and sometimes conflicting research on the most appropriate topical and systemic methods 
of fluoride delivery has been carried out. Systematic reviews have concluded that fluoride 
toothpastes, mouth rinse, varnishes and gels are effective in reducing caries activity regardless of 
fluoridated water exposure. Fluoridated toothpastes are suggested to be the most practical vehicle 
for fluoride delivery due to high compliance. However the caries reduction effect of fluoridated 
toothpaste can be compounded by additional topical fluoride exposures such as mouth rinses and 
varnishes (Marinho et al, 2008). 
 
The effectiveness of fluoride releasing orthodontic materials has also been demonstrated. A 
systematic review assessing orthodontic bracket adhesives suggested that fluoride releasing glass 
ionomers may reduce local decalcification (Benson et al, 2004). Fluorides releasing elastomeric 
modules have also been suggested as an effective method of reducing orthodontic demineralisation 
(Banks et al, 2000). 
 
Fluorosis and toxicity 
 
An adverse side effect of excessive fluoride exposure is fluorosis. Fluorosis is a dose related response 
to excess fluoride ingestion during pre-eruptive tooth development resulting in hypo-mineralisation 
of enamel and formation of surface and subsurface porosities. The extent can vary from mild enamel 
translucencies to deep pitting of enamel (Figure 1.3.1).  The York Review (McDonagh et al, 2000) 
found that at 1ppm fluoridation of water, 12.5% of the population developed fluorosis resulting in 
an aesthetic concern. The critical exposure time for fluorosis is between 1 – 4 years, with a minimal 
risk after the age of 8 years. 
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Figure 1.3.1 Demonstrating severe Fluorosis (Yildiz and Celik, 2013) 
   
 
Fluoride toxicity can occur due to highly excessive systemic ingestion. Adverse gastrointestinal 
effects can occur at levels of 1mg/kg with symptoms including nausea, vomiting, abdominal pain and 
diarrhoea. Acute toxicity resulting in hyperkalemia can cause convulsions, cardiac arrest and 
respiratory failure, with lethal toxic doses at 32-64 mg/kg. This is equivalent to ingestion of 3.3 70g 
tubes of toothpaste for a 60kg adolescent (Welbury et al, 2005; Baltazar et al, 1980). 
 
 
1.4 Caries Remineralisation with CPP- ACP 
Casein phosphopeptide-amorphous calcium phosphate has been suggested for use in caries 
prevention since the 1980’s and as a mineralising agent since the 1990’s (Reynolds, 1998). A group 
of peptides, Casein Phosphopeptides (CPP) have been shown to stabilise and preserve calcium and 
phosphate ions as nanoclusters in a stable solution known as Amorphous Calcium Phosphate (ACP). 
ACP is highly soluble and readily converted to Hydroxyapatite (HA) and is therefore a suitable 
mineralising agent (Tung and Eichmiller, 1999). 
 
Previous difficulty in using calcium and phosphate ions in remineralisation was due to their low 
solubility especially in the presence of fluoride. Therefore soluble calcium and phosphate ions are 
not easily incorporated into dental plaque or localised at the tooth surface at high enough 
concentrations to promote adequate diffusion required for remineralisation. Subsequently CPP-ACP 
was developed with CPP stabilising high concentrations of calcium and phosphates together with 
fluoride by binding to plaque and the pellicle layer at the tooth surface (Reynolds, 2009). 
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CPP-ACP mechanism of action 
 
Calcium phosphate reservoir 
Anticariogenic activity has been attributed to the ability of CCP to localise ACP at the tooth surface 
thereby increasing calcium phosphate levels in the dental plaque (Reynolds, 1997). 
 
Bacterial adhesion  
CPP-ACP may inhibit cariogenic streptococci bacterial adhesion to tooth surface therefore inducing a 
non-cariogenic plaque formation (Schupbach et al, 1996). 
 
Antibacterial                                                                                                                                                      
CPP-ACP competes with calcium for calcium plaque binding sites resulting in a highly extracellular 
free calcium concentration which may have bactericidal or bacteriostatic effects along with an 
additional anti-plaque effect (Rose, 2000). 
 
Prevent demineralisation and improved remineralisation  
CPP-ACP has been shown to remineralise enamel subsurface lesions at a rate of 1.5 – 3.9 x 10⁻⁸mol 
hydroxyapatite m⁻² s⁻¹ (Reynolds, 1997). CPP-ACP can stabilise 100 times more calcium phosphate 
than neutral pH solutions. The formation of hydroxyapatite in the lesion produces phosphate and 
acid, which diffuses out of the lesion. CPP-ACP consumes the acid generated during enamel lesion 
remineralisation and generates more calcium and phosphate ions required for diffusion into the 
lesion.  CPP-ACP has been shown to inhibit caries activity by a dose related response (Reynolds 1995, 
1998). Enamel lesions which have remineralised after topical exposure to CPP-ACP are less 
susceptible to future acid exposure due to improved crystallinity and lower micro-strain than normal 
dental enamel (Iijima et al, 2004). 
 
Tooth Erosion  
CPP-ACP may prevent tooth erosion by a combination of suppressing demineralisation and 
enhancing remineralisation. Studies have shown reduced levels of enamel erosion in enamel 
previously exposed to CPP-ACP (Rees et al, 2007). 
 
CPP-ACP and Fluoride 
Plaque enzymes such as phosphatases and peptidases can cause partial degrading of CPP-ACP 
products. The addition of fluoride to CPP-ACP limits this phosphatase action (Vitorino et al, 2005). 
Fluoride interacts with CPP-ACP to produce a stable amorphous calcium fluoride phosphate (ACFP) 
nanocluster at the tooth surface. CPP-ACFP may provide a source of soluble calcium, fluoride and 
phosphate that is more resistant to pH changes. A CPP molecule can adhere to 25 Calcium ions, 15 
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phosphate ions and 5 fluoride ions making it an effective delivery system (Cross et al, 2005). When 
fluoride is incorporated into CPP-ACP paste, it has been shown to further promote remineralisation 
and enhance caries resistance of root surfaces (Garcia-Godoy et al, 2009).  
 
Cochrane (2008) proposed that at pH levels below 5.5, CPP-ACP solutions containing Fluoride (CPP-
ACFP) produced greater ion diffusion activity resulting in an increased remineralisation effect.  
Reynolds et al (2008) concluded that a dentifrice with 2% CPP-ACP and 1100ppm F was superior to 
all other CPP-ACP and fluoride combinations.  However fluoride has been shown to interact with ACP 
and may precipitate out as calcium fluoride resulting in both inorganic components being ineffective 
(Azarpazhooh and Limeback, 2008). Recent studies suggested that CPP-ACP paste containing 
900ppm Fluoride has minimal improvements in remineralisation over regular CPP-ACP pastes or 
regular fluoride pastes alone (Beerens et al, 2010; Vanichvatana et al, 2013). 
 
CPP-ACP evidence 
Early in situ studies evaluating CPP-ACP for remineralisation demonstrated promising results.   Cai et 
al (2003) carried out a randomised, double blind in situ study on remineralisation of enamel 
subsurface lesions using sugar-free lozenges containing CPP-ACP.  CPP-ACP lozenges of over 18.8 mg 
were effective in promoting remineralisation of early non-cavitated lesions. Shen et al (2001) in a 
similar in situ study concluded that sugar-free chewing gum containing 18.8mg or more resulted in 
statistically significant increases in enamel remineralisation relative to a control chewing gum.  
Reynolds (1998) also suggested that exposure to CPP-ACP 1mg solutions twice a day resulted in a 
reduction in enamel mineral loss of 51% compared to the control. 
 
However, more recent in vitro studies evaluating the remineralisation effect of GC Tooth Mousse™ 
(which incorporates CPP-ACP) concluded that there was no statistically significant difference in 
remineralisation efficacy of GC Tooth Mousse™ compared to saliva or water (Lovel, 2008; Benson, 
2009; Bichu et al, 2013). It was acknowledged however that an in vitro model may not be the most 
appropriate setting and the lack of a biologically active biofilm may be the reason for the limited 
remineralising ability demonstrated. It was recommended that future in situ and in vivo randomised 
control trial may be more appropriate.   
 
A number of QLF (Quantitative Light-Induced Fluorescence) studies assessing in vivo post-
orthodontic remineralisation of white spot lesions have demonstrated that Tooth Mousse™ has a 
beneficial and statistically significant remineralising effect (Bailey et al, 2009; Atkin et al, 2012; 
Vashisht et al, 2013). However a similar study found that although increased remineralisation of 
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white spot lesions occurred with CPP-ACP cream, this was not significantly more effective than with 
regular fluoridated toothpaste (Brochner et al, 2011). 
 
A recent TMR in situ randomised controlled trial assessed the remineralisation of subsurface lesions 
in orthodontic patients during treatment using GC Tooth Mousse™ (Bryniarska, 2012). It was 
concluded that there was no statistically significant difference in remineralisation noted. However a 
large number of samples were lost in this study and this may have affected any conclusions which 
could be drawn. Further in situ randomised controlled trials were recommended with an increased 
emphasis on procedural planning to reduce loss of samples during the in situ phase and the TMR 
sectioning and polishing phase. Another in situ randomised controlled trial compared the 
remineralisation abilities of GC Tooth Mousse™, GC Tooth Mousse Plus™, and a range of fluoride 
concentration solutions. They found that only GC Tooth Mousse™ and GC Tooth Mousse Plus™ 
provided high concentrations of stabilised, bioavailable calcium, phosphate and fluoride ions in 
saliva. This enhanced bioavailability produced a statistically significant increase in remineralisation of 
enamel subsurface lesions in situ compared with fluoride solutions (Shen et al, 2011). 
 
A recent systematic review of the literature (Li et al, 2014) concluded that CPP-ACP was clinically 
proven as a long-term remineralising agent and its enhanced remineralisation effect was comparable 
to that of fluoride. However the advantages of fluoride as a supplement to CPP-ACP is still unclear 
and further high quality randomised controlled trials were recommended. 
 
Tooth Mousse™ (GC Corporation, Europe) 
Tooth Mousse™ is a water based, sugar free dental topical cream containing RecaldentTM CPP-ACP 
(10% w/w). The manufacturers of Tooth Mousse™ recommend usage of the product in a number of 
situations;  
 an acidic oral environment, 
 active decay, presence of white spot lesions  
 sensitive teeth, erosion or tooth wear  
 during tooth whitening procedures  
 during orthodontic treatment  
 dry mouth and dehydration 
 suffering from morning sickness during pregnancy  
 medically compromised patients 
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Picture 1.4.1.  Tooth Mousse™ (GC Corporation, Europe) 
 
 
Tooth Mousse™ Application 
Direct Application 
1. After brushing your teeth, apply a sufficient amount to the tooth surface using a clean dry 
finger or cotton tip.   
2. Leave on the tooth surface undisturbed for a minimum of 3 minutes.   
3. Then use your tongue to spread the applied crème throughout the mouth.   
4. Hold in the mouth for a further 1-2 minutes.  The longer GC Tooth Mousse™ and saliva are 
maintained in the mouth, the more effective the result. 
5. Expectorate thoroughly and if possible avoid rinsing.  Any GC Tooth Mousse™ remaining on 
the tooth surface can be left to gradually dissipate. 
6. Do not eat or drink for 30 minutes following application. 
 
Tray Application 
1. Before use, clean the custom tray thoroughly under running water.   
2. Apply a sufficient amount of cream into the tray and sit the tray in place.   
3. Leave the tray undisturbed in the mouth for a minimum of 3 minutes. 
4. Remove the tray, and then use your tongue to spread the crème throughout the mouth. 
5. Hold in the mouth for a further 1-2 minutes.  The longer GC Tooth Mousse™ and saliva are 
maintained in the mouth, the more effective the result.   
6. Expectorate thoroughly and if possible avoid rinsing.  Any GC Tooth Mousse™ remaining on 
the tooth surface can be left to gradually dissipate. 
7. Do not eat or drink for 30 minutes following application. 
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1.5 Methods of study design 
Different study models can be used to study the process of enamel demineralisation  
 In vitro 
 In vivo 
 In situ 
 
In vitro 
In vitro (Latin for “In Glass”) refers to an experiment in which the effects of various biological entities 
are being performed outside of the normal biological context. This would involve dental samples, 
whether human or animal, being tested in the laboratory setting.   
 
The advantages of an in vitro model are that it may be relatively inexpensive and less time 
consuming. Due to the laboratory setting, destructive quantification techniques may be utilised such 
as TMR which would otherwise be prohibited in the in vivo setting. Another advantage of an in vitro 
setting is that experimental conditions can be closely controlled and monitored, compared to in vivo 
studies which may suffer from a wide range of confounding environmental variables. Also in vitro 
studies may benefit from less restrictive ethical considerations compared to in vivo and in situ 
models (White, 1995). 
 
The main disadvantage however of in vitro systems are that they do not accurately replicate the real 
life biological situation. Caries is a complex process and it is unlikely that a laboratory setting can 
ever fully replicate the in vivo scenario. It is extremely difficult to simulate the microbiology 
environment and the effect of salivary flow and salivary composition. Demineralisation and 
remineralisation rates are faster in vitro than in vivo due to an increased uptake and reactivity of 
fluoride (White, 1995). 
 
Both bovine and human enamel systems can be utilised to simulate the in vivo process of 
demineralisation. Although bovine enamel is more readily available than human enamel, a major 
disadvantage is that bovine enamel is softer and more porous than human enamel and therefore 
demineralises more readily. Human enamel, where applicable should be seen as the gold standard. 
Human enamel is more representative of the true biological situation and therefore the trial results 
should be more applicable and relevant (Mellberg, 1992).  
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In Vivo 
In vivo (Latin for "within the living”) refers to experiments in which the effects of various biological 
entities are carried out within the living organism. This would involve assessing the carious process 
in the patient’s normal oral environment on living dental tissue.  
 
Non-destructive techniques are normally utilized such as QLF (Quantitative Light-Induced 
Fluorescence), unless dental extractions are deemed necessary as part of the orthodontic treatment 
plan. In such a case an in vivo caries model may involve monitoring of the demineralisation- 
remineralisation process on healthy dental tissue followed by extraction and quantitative analysis. 
 
The key advantage an in vivo model is that the teeth are in their most natural state in the natural 
biological oral environment and therefore the trial results should be more applicable and relevant.  
 
The major disadvantage of destructive in vivo techniques is patient recruitment. There is often a 
limited availability of suitable patients with suitable teeth which require extractions. Also this system 
is only applicable for the early stages of treatment, as any increased period of observation will result 
in delayed extractions and therefore increasing the overall treatment time for the patient. Therefore 
this model is unsuitable to observe enamel changes over a longer duration of time (Mellberg, 1992). 
 
 
In situ 
In situ (Latin for "on site”) refers to experiments in which biological systems are attempted to be 
reproduced or simulated in the living organism. This would involve the use of appliances or other 
devices which create defined conditions being placed in the oral cavity to simulate and analyse the 
dental caries process (Zero, 1995). This is seen to be an amalgamation between the in vitro study 
and the in vivo clinical trial.  
 
The in situ caries analysis technique usually involves a specimen of human or bovine enamel being 
placed in a customised holder which is then attached intra-orally. The use of a baseline control 
sample derived from the same tooth will allow for comparison with the in vivo sample.  
 
The advantage of an in situ model is that it takes place in the oral environment and therefore 
replicates many of the complex biological aspects of the carious process which can not be replicated 
by in vitro studies. As a result we benefit from simulation and analysis of the natural caries process 
without causing irreversible damage to the patient. With adequate study design it should be possible 
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to control experimental variables and reduce bias. The possibility of destructive analysis allows for 
improved scientific analysis with an increased reproducibility and validity. 
 
In situ trials are generally of a shorter duration, thereby reducing the ethical implications and 
financial restrictions experienced by longer term clinical trials. Usually the in situ model can be 
utilised at various stages of orthodontic treatment so therefore will not hinder or restrict the 
patients typical orthodontic treatment progress (Zero, 1995). 
 
A major disadvantage however of the in situ model is that the techniques involved are clinically very 
demanding and require skilled analytical expertise.  The number of patients is usually restricted due 
to the extensive resource and time requirements.  Patient compliance is crucial and loss due to 
follow up is a common problem (Zero, 1995). 
 
Randomised Controlled Trials 
A randomised controlled trial (RCT) is a prospective interventional study, designed to assess the 
effects of one or more interventions when compared with a control. This control group can either 
receive no treatment, a placebo, or the best currently available standard of care. Commonly in 
cariology studies fluoride is the control remineralisation agent.  A major advantage of a RCT design is 
that they reduce the influence of bias and confounding factors.  
 
Bias 
Bias is defined as any factor or process that causes systematic deviation of the trial results or 
conclusions away from the truth (Jadad, 1998). There are three main types of bias that can occur in 
clinical trials; selection bias, instrument bias and observer bias. Selection bias is a systemic error in 
the patient recruitment process which results in a non-representative sample. In randomised 
controlled trials this is minimized through an effective recruitment and randomisation procedure.  
Instrument bias is a systematic error in measurement of the outcome or statistical analysis which 
can reduce the accuracy and reproducibility of the results. In cariology studies this can be minimised 
by utilising accurate mineral analysis techniques such as Transverse Microradiography.   
 
Randomisation 
Randomisation ensures all study participants have an equal chance of being allocated to any group 
within the study. Random allocation ensures that baseline characteristics of the groups are 
comparable. It is possible to balance the groups for known factors which affect treatment outcome, 
however this is not possible for unknown confounding factors. A confounding factor has a 
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relationship with both the potential cause and the outcome but is not involved in the causal 
pathway (Bruce et al, 2008). These are often unknown and can either under estimate or over 
exaggerate results of the study. Randomisation ensures that unknown confounding factors that may 
influence the study are kept to a minimum.  
 
Blinding 
Blinding of the participant and/or the investigator reduces the risk of bias in a study. A single blind 
trial is where the participant is unaware of the treatment allocation. A double blind trial is where the 
participant and the investigator are both unaware of the treatment allocation. This ensures that the 
investigators behaviour and approach is not influenced by the knowledge of what treatment the 
participant is receiving. It is however difficult to blind the investigator, particularly in dental studies 
where there may be an obvious difference in the treatments provided. It is important in cariology 
studies to ensure the investigator is blinded during the data analysis stage. This is achieved by 
Coding of samples so the investigator is unaware of the treatment group allocation. This is 
sometimes referred to as a triple blind trial. 
 
Cross-over trials 
A cross-over trial is a longitudinal study in which participants receive a sequence of 
different treatments at different time periods. Cross-over trials enable each participant to act as 
their own control, allowing for inter and intra-participant comparison. Cross over designs are often 
utilised in In situ demineralisation studies as this allows for statistically and clinically significant 
results with fewer participants (Jadad, 1998).  A wash out period between treatments is essential to 
eliminate any carry-over effects.  
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1.6 Methods of Mineral Evaluation 
The caries process can be diagnosed and monitored by assessing the amount and change of mineral 
content within the tooth. Quantitative methods of analysis allow for accurate measurement of small 
changes in individual lesions and assessment of lesion progression (Ten Bosch and Angmar-Mansson, 
1991). 
 
Quantitative Light-Induced Fluorescence (QLF) 
QLF is a non-destructive diagnostic device used for early detection of demineralisation in enamel 
and dentine. QLF utilises the differential fluorescence of a low fluorescent white spot lesion in 
comparison to highly fluorescent healthy enamel.  Blue light (370 nm) is directed towards the tooth 
which excites the enamel and causes it to fluoresce in the yellow-green region. A yellow high-pass 
filter (540 nm) is used to remove the blue portion of the light. This fluorescence can then be 
observed using an intraoral camera. If an enamel lesion is present, an increase in light scattering is 
observed relative to the surrounding enamel. This change in fluorescence between sound enamel 
and the lesion is measured using a computer program. By using a reconstructed algorithm of 
fluorescence radiance for healthy enamel and the actual fluorescence radiance of the demineralised 
lesion, the percentage change can be calculated and therefore the relative mineral loss (De Josselin 
de Jong, 1995). 
 
QLF has been shown to be sensitive and reproducible.  Elton et al (2009) suggested that QLF is highly 
effective for measuring the subsurface loss of mineralisation but is less effective at measuring lesion 
depth. QLF ability to measure demineralisation has been shown to be comparable to destructive 
TMR technique (Lovel, 2008).  It has therefore been suggested as an appropriate method for in vivo 
quantification of early smooth surface caries (Pitts, 2009).   
 
QLF imaging has been shown to be an effective in vivo method to detect and monitor levels of 
enamel demineralisation during orthodontic treatment. It has also been suggested for use as an 
effective visual oral hygiene aid, providing improved analysis and awareness of plaque accumulation 
levels (Miller, 2014). 
 
Transverse Microradiography (TMR) 
TMR is a destructive technique which requires cuts to be made to the specimen and microsamples  
removed for analysis. TMR is based on the measurement of x-ray absorption by a tooth section 
compared with absorption by a simultaneously exposed standard (Ten Bosch and Angmar-Mansson, 
1991). 80μm sections of the enamel sample are cut perpendicular to the anatomical tooth surface 
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and placed on high-resolution photographic film along with an aluminium calibration stepwedge and 
irradiated with monochromatic x-rays. Absorption of X-rays by the tooth sample and stepwedge 
directly affect the optical density of the developed film. This optical density is used to calculate 
mineral content. Dedicated software and image analysis systems using a video camera (CCD) are 
then used to evaluate microradiograph optical densities and to generate mineral content profiles. 
Three main parameters are obtained from the analysis of mineral content profiles, 
• Mineral loss ΔZ (vol%μm) 
• Lesion depth Ld (μm)  
• Lesion width Lw (μm)  
 
Mineral loss is the difference between the mineral content of sample and that of the sound enamel. 
Lesion depth and lesion width values are both determined from the mineral distribution.  The 
accuracy of TMR for mineral loss ΔZ is 200 vol%μm and lesion depth (Ld) is approximately 5 μm. 
(Arends & Ten Bosch, 1992).  However incorrect measurements can be created if the lesion is not 
uniform. 
 
A major disadvantage of the TMR process is that it requires destruction of the sample and therefore 
limiting its use in the In vivo study design (Elton and Cooper, 2008). Technical difficulties include 
handling and sectioning of small enamel samples and in creation of the required parallel sections. 
Other limitations include an inability to measure less than 10 μm from the anatomical surface due to 
the inherent curvature of the samples (White et al, 1992). Despite these limitations TMR is generally 
accepted as the gold standard in direct quantification of mineral change. A comparison of TMR 
results with QLF is routinely used for validation. 
 
1.7 Summary 
Orthodontic demineralisation is a common adverse side effect of orthodontic treatment. The 
evidence base for the use of CPP-ACP in enamel remineralisation is limited and conflicting. This study 
set out to determine the remineralising properties of Casein phosphopeptide amorphous calcium 
phosphate toothpaste in orthodontic patients using an in situ design.  
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2.0  Trial Aims and Objectives  
 
2.1 Aims 
To determine the level of demineralisation or remineralisation of sub-surface carious lesions placed 
in situ on an orthodontic appliance and treated with fluoride toothpaste (1450ppm) or a 
combination of fluoride toothpaste (1450ppm) and GC Tooth Mousse™. 
 
2.2 Objectives 
To assess the degree of change in mineralisation of subsurface lesions following the application of 
fluoride toothpaste (1450ppm)  and GC Tooth Mousse™ with Transverse Microradiography (TMR) as 
volume mineral loss (ΔZ), lesion depth and lesion width. 
 
2.2 Null Hypothesis 
This study will test the null hypothesis that there is no difference between the remineralising 
potential abilities of GC Tooth Mousse™ and normal fluoride toothpastes in orthodontic patients. 
Therefore there will be no statistically significant difference between volume mineral loss (ΔZ), 
lesion depth and lesion width. 
 
3.0 Trial Design 
3.1 Ethics 
Ethical approval was obtained from the National Research Ethics Service (NRES) and the NHS 
Research and Development Offices. This study was given the REC reference number: 13/NW/0742.  
The trial was also registered on Current Control Trials http://www.controlled-
trials.com/ISRCTN04899524/. 
 
3.2 Trial Design 
The design was a randomised cross-over in situ study. This involved the use of prepared enamel 
lesions of previously extracted premolar teeth being placed in situ. The interventions of fluoridated 
toothpaste and fluoridated toothpaste plus GC Tooth Mousse™ were given to the orthodontic 
participants in a randomised order with a wash out phase constituting a cross-over study. 
 
3.3 Trial Setting 
The trial setting was the Health Services Research Department and the Orthodontic Clinic Liverpool 
University Dental Hospital (LUDH). 
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3.4 Sample size calculation 
The primary outcome variable was percentage mineral loss ΔZ , calculated by dividing the sample 
value by the control value, and multiplying by 100. Data were used from a previous study 
(Bryniarska, 2012) using the Transverse Microradiography (TMR) technique. From this study the 
standard deviation of the data between the test and control groups was 50. A sample size of 12 
participants would allow detection of a difference of 45% ΔZ between the two groups, with 80% 
power, at the 5% significance level. However this previous study had fundamental procedural 
difficulties which resulted in incomplete data sets and this may have resulted in more variable data 
than would be expected. If the standard deviation in this study was reduced to 30, then this would 
allow detection of a difference of 28% ΔZ between the two groups with 80% power, at the 5% 
significance level. 
 
4.0 Selection and withdrawal of participants 
Participants entering the trial were orthodontic patients taken from the Liverpool Dental Hospital 
waiting list, which therefore includes only patients assessed and deemed suitable for NHS treatment 
or for training purposes.  This selection bias may unfortunately reduce the representativeness of the 
sample population compared to the overall population. The selected patients were those who were 
undergoing fixed appliance orthodontics. All participants were required to provide informed consent 
both written and verbal.  
 
4.1 Inclusion criteria 
The participants were required 
 To be between the ages of 12 to 17 years 
 To have adequate space  in their  lower premolar region  to  allow placement of the carrier  
 To be in a suitable rigid archwire to allow placement of the carrier 
 To be in good general health and oral health 
 
4.2 Exclusion criteria 
The participants were excluded if 
 They were allergic to milk products  
 They were taking or had taken antibiotics in the last 2 months 
 They were unable to maintain adequate oral hygiene 
  
Patients recently taking antibiotics were excluded as this can significantly alter the oral micro-flora, 
with Streptococcus strains particularly affected (Edlund and Nord, 2000). 
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4.3 Withdrawal of participants 
Participants were removed from the study at any stage if they withdrew consent at their request. If 
for any reason the patient required their fixed appliance to be removed due to a clinical decision 
separate to this study, then they would also be removed from the study. 
 
4.4 Consent 
At a routine orthodontic appointment, eligible patients were invited to participate in the study. 
Participant information leaflets were provided to the parents and the children in ‘plain English’ 
explaining the purpose of the study (Appendix 2a, 2b). If the participant was under 16 years old they 
were provided with an assent form and the parent/guardian with a consent form (Appendix 3a, 3b). 
If the participant was 16 years or over they were provided with a consent form (Appendix 3c).  
 
4.5 Participant compliance 
Intervention A and B pastes were weighed before being provided to the participant. The participants 
were requested to bring the tube of paste/s with them on their review appointment. The tubes were 
then re-weighed to assess the amount used in the four-week period, and therefore give a suggestion 
of compliance. 
 
4.6 Randomisation procedure 
Each eligible participant was allocated a subject number as they were recruited to the study. 
Intervention order was randomised by a statistician who was not involved in the recruitment process 
using simple computer generated random allocation (Table 4.6.1). The participants were 
randomly allocated to one of two possible orders of intervention;  AB  or BA.  
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Table 4.6.1 Participant number and randomised order of interventions 
Participant  Intervention Intervention 
1 B A 
2 B A 
3 B A 
4 A B 
5 A B 
6 B A 
7 B A 
8 A B 
9 A B 
10 B A 
11 A B 
12 A B 
 
 
5.0 Trial Procedures and Methodology 
5.1 Investigational medicinal products 
The interventions were as follows; 
A. Standard fluoride toothpaste (1450ppm). 
B. Standard fluoride toothpaste (1450ppm) and topically applied Tooth Mousse™ (GC 
Corporation, Europe.  10% w/w CPP-ACP) to be applied directly to the teeth. 
 
‘Tesco Toothpaste 75Ml’ was chosen as the standard fluoride toothpaste due to the minimal 
ingredients, and additives present. The ingredients of Tesco Toothpaste Ingredients are listed as : 
Aqua, Sorbitol, Hydrated Silica, Sodium Lauryl Sulphate, Aroma, Cellulose Gum, PEG-32, Sodium 
Fluoride, Sodium Saccharin, Hydroxyethylcellulose, Limonene, CI 77891.  Contains Sodium Fluoride 
1450ppm. 
 
The ingredients of Tooth Mousse™ (GC Corporation, Europe) are listed as: Pure water, Glycerol, CPP-
ACP, D-sorbitol, Silicon Dioxide, CMC-Na, Propylene glycol, Titanium dioxide, Xylitol, Phosphoric acid, 
Guar gum, Zinc Oxide, Sodium Saccharin, Ethyl p-hydroxybenzoate, magnesium oxide, Butyl p-
hydroxybenzoate, Propyl p-hydroxybenzoate. 
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5.2 Visit by visit example 
The trial consisted of four distinct 4 week phases, including a pre-trial wash out period and a mid-
treatment wash out period. Each participant received both treatment interventions in a randomised 
order.  An example of the sequence is outlined below for allocation AB. 
 
 Visit 1-Pre-trial wash out (4 weeks) 
Routine orthodontic exam 
Participant provided with standard fluoride toothpaste, toothbrush and instructions 
 
 Visit 2-Treatment A (4 weeks) 
Routine orthodontic exam 
Carrier with enamel specimen attached to lower arch wire 
Treatment A paste is given to participant with instructions on its use 
 
 Visit 3-Mid- treatment wash-out   (4 weeks) 
Routine orthodontic exam   
Carrier with enamel specimen removed and sent for analysis 
Participant provided with the standard fluoride toothpaste and instructions 
 
 Visit 4-Treatment B (4 weeks) 
Routine orthodontic exam  
New carrier with enamel specimen attached to lower arch wire 
Treatment B pastes are given to participant with instructions on its use 
 
 Visit 5-Trial Competition 
Routine orthodontic exam   
Carrier with enamel specimen removed and sent for analysis 
 
All participants were provided with the standard fluoride toothpaste and a toothbrush and asked to 
brush their teeth for two minutes twice a day with a pea sized amount for the 4-week phase. 
Intervention B participants were also provided with Tooth Mousse™ and advised to apply directly to 
the teeth for 5 minutes. The participants were asked not to use any other toothpaste or mouth 
rinses during this trial. The instructions were provided in written form (Appendix 1a, 1b). 
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5.3 Trial Flow Chart  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4 Duration of trial 
The duration of the clinical trial per participant was 16 weeks.  4 weeks pre-trial wash out, 4 weeks 
for the 1st intervention (A/B),  4 weeks mid treatment wash out and 4 weeks  for the 2nd intervention 
(B/A). The total duration of the clinical trial was approximately 9 months as this was dependent on 
participants being at an adequate orthodontic stage to allow carrier placement. 
 
5.5 Blinding 
All tubes provided to the participant were covered with opaque insulation tape (Duck Original White 
Tape 50, ShurTech Brands Avon, UK) so the participant was unaware to the paste being used. Once 
the enamel samples were removed from the carrier following the in situ phase, the samples were 
recoded by a research technician not directly involved in the study. The samples were then 
sectioned and analysed so the principal investigator was blinded to the participant and intervention 
during analysis therefore reducing bias. Following TMR analysis the coding was revealed. 
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5.6 Creation of artificial subsurface lesions 
The creation of artificial carious lesions was similar to that outlined by Benson (2009) and Bryniarska 
(2012). Non-restored human premolar teeth extracted for orthodontic purposes, were collected and 
stored in distilled water containing thymol, thereby inhibiting bacterial growth (Sikkema et al, 1995). 
The teeth were visually examined to confirm the absence of any stains, caries or cracks. The teeth 
were also examined under QLF imaging for increased detection of surface irregularities. Selected 
teeth were then lightly abraded with fine 1.200-grit abrasive paper (English abrasives bP320A, 
English abrasives and Chemicals, UK) to remove the outermost enamel and remnants of the pellicle 
from the buccal surface.  
 
Teeth were then varnished with acid resistant nail varnish (Max Factor, Nailfinity, Weybridge, UK) 
except for a window approximately 7mm by 3mm on the buccal surface where the demineralized 
lesion was to be created. Teeth were then mounted on glass rods using greenstick compound and 
immersed into an acid buffer demineralising gel at room temperature as described by Edgar (1983) 
(Figure 5.6.1). This was produced by mixing 0.1M lactic acid (Merck, UK) and 0.1M sodium hydroxide 
(BDH, UK) until a pH of 4.5 was reached. 6% (w/v) hydroxyethylcellulose (SigmaAldrich.Co.Ltd, UK) 
was added and mixed with an electric mixer (Kenwood, UK) to give a final gel consistency similar to 
that of “wallpaper paste”.   
 
Figure 5.6.1 showing placement of mounted teeth into demineralising gel 
 
 
The teeth were submerged in this demineralising gel for a period of 5-7 days.  At this stage they 
were removed, and visual examination was used to detect if a deminerlalised lesion was present. 
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QLF imaging was also utilised to confirm the presence of an even demineralised subsurface lesion 
(Figure 5.6.2) but also to ensure that any lesions of poor quality or uneven distribution were 
identified and excluded (Figure 5.6.3).  If no lesion had developed the teeth were submerged back in 
the demineralisation gel for another 2-3 days and then re-anlaysed. 
 
Figure 5.6.2 showing evenly demineralised lesion under white light and QLF  
 
 
Figure 5.6.3 showing unevenly demineralised lesion under white light and QLF  
 
 
Adequately demineralised teeth were withdrawn from the gel, rinsed thoroughly with distilled 
water, gently blotted dry and left to air dry.  The block of enamel containing the lesion was then cut 
from the crown with a margin of sound enamel using a diamond disc (Skilldental, High Wycombe, 
UK. The lesion was then mounted on green stick and divided into 3 sections; 1 control section  and 2 
experimental  sections using a diamond wire saw (Well, Walter Ebner, Le Locle, Germany),(Figure 
5.6.4 + 5.6.5). 
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Figure 5.6.4 Tooth mounted on green stick ready to be sectioned with the diamond wire saw 
  
 
Figure 5.6.5 Diagrammatic representation of Enamel lesion sectioning 
 
 
The control section had 2 TMR slices cut of approximately 280μm width, which underwent TMR 
preparation and polishing (described in section 5.9). Immediate TMR analysis was carried out to 
assess the extent of mineral loss and therefore suitability of inclusion in the trial. 60 teeth in total 
were prepared by this method. However, only teeth with a uniform and regular lesion, with mineral 
loss range of 900-1700 vol%μm were selected. Of the 60 teeth demineralised only 16 were found to 
have an adequately even demineralisation suitable to be used in the trial. 
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5.7 Creation of enamel carrier design 
The carrier design used was a modified version of that described by Bryniarska (2012). The 
components required to produce one stainless steel carrier were; (Figure 5.7.1)   
 2 small rectangular rings formed from 0.8mm stainless steel orthodontic wire 
  (DB orthodontics  Yorkshire ,UK ) 
 2 Stainless steel molar bracket bases (American Orthodontics, Ref 095, 0.225 x 0.120) 
 1 Slide-on surgical ball hook,  0.021" x 0.025".  (Orthodontic Technology, USA) 
 Dacron gauze (polyester mesh P/N: PETKM3002, USA) 
 
Figure 5.7.1 Components for enamel carrier construction 
 
 
 
 
 
 
 
 
 
 
The 0.8mm stainless steel orthodontic wire was hand bent into a rectangular shaped ring and was 
spot welded together (Microwelder, Type 95, SLEE, London, UK). This rectangular shaped ring was 
then spot welded to the molar bracket base (Figure 5.7.2). The joins were polished with a green 
stone polishing bur (Dura-green Stone PC2, Shofu, Kent, UK) to remove any sharp or rough edges 
that could cause intra-oral irritation. 
 
Figure 5.7.2 Bracket base and rectangular wire welded together 
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The slide-on surgical ball hook with internal dimensions 0.021”x 0.025” was then spot-welded to the 
back of a stainless steel molar bracket base. The ball was positioned in the middle of the bracket 
base. As this join was deemed to be vulnerable to breakage in situ, this was re-inforced with 
additional solder and then repolished (Figure 5.7.3). Non-fluoride borax flux (Flux Low-Fusing, 
General Dental Supplies, Dentecon Inc, California, USA) was used to ensure this did not result in 
fluoride ion release and affect the demineralisation process. 
 
Figure 5.7.3 Ball hook welded to bracket base and polished 
 
 
The experimental enamel specimens were then reduced in size as required to fit inside the 
rectangular carrier. The specimen was then adhered to the bracket base using nail varnish (Max 
Factor, Nailfinity, Weybridge, UK). 
 
Figure 5.7.4 Trimmed enamel specimen prior and post placement in carrier 
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Dacron gauze was placed over the enamel specimen carrier and another rectangular stainless steel 
ring positioned above. The two stainless steel rings were then carefully spot welded together to 
produce the completed carrier (Figure 5.7.5). The manipulation for this procedure was technically 
difficult and great care was required to avoid enamel sample damage by the spot welder. If the 
dacron gauze was too dry it became very friable and singed due to the heat of the spot welder, 
which would result in early detachment from the carrier.  If the gauze was slightly moistened and 
then let to dry at room temperature for 5 minutes, it retained a small amount of moisture to prevent 
it from being friable or combusting on heat application but not enough moisture that it would affect 
the spot welding join between the two metals. 
 
Figure 5.7.5 Completed enamel carrier 
 
 
 
 
 
 
 
 
 
 
The completed carrier was then placed in a 1.5 ml-capped tube with a small drop of water to 
maintain moisture content. All experimental sections were sterilized by gamma irradiation with dose 
4080 Grays over 3 days under a cobalt source. This effectively sterilises the sample from bacteria 
without causing any discoloration or mineral content changes (Amaechi et al, 1999). The sterilised 
enamel carrier was then stored in a refrigerator at approximately  3°-5° until required for the clinical 
trial. 
 
5.8 Intra-oral carrier placement 
At a routine orthodontic appointment the enamel carrier was attached.  With the archwire out of 
the mouth, the enamel carrier was threaded onto the wire posteriorly. It was positioned in the lower 
premolar region and then the wire was carefully inserted intra-orally. The carrier placement was 
then adjusted so it was located passively in the premolar embrasure space (Figure 5.8.1). The patient 
was given time to feel and check that the carrier was comfortable and any required adjustments 
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were carried out at this stage. The patient would ideally be in a full size rectangular 0.019” x 0.025” 
wire as this would reduce excess movement of the carrier. The carrier was placed on the side which 
had the most appropriate embrasure space to ensure a comfortable fit. Benson (1999) found that 
there was no difference in remineralising effect between placing in situ enamel on the dominant or 
non-dominant brushing side of the mouth. 
 
Figure 5.8.1 Enamel carrier in situ 
 
 
5.9 TMR preparation 
Returned enamel carriers were placed in an acetone solution (VWR International Ltd, Poole, 
England) to dissolve the nail varnish. A surgical scalpel (SKU-0511, Swann Morton, Sheffield, England) 
was used to carefully remove the Dacron gauge from the enamel carrier. The enamel specimen 
could then be easily removed from the carrier while minimising any damage. The carrier was then 
discarded into the sharps bin. The enamel specimen was then re-submerged in acetone solution to 
ensure all nail varnish residue had been removed (Figure 5.9.1). The sample was thoroughly rinsed 
with distilled water and stored in a new 1.5ml capped tube ready for sectioning. 
 
Figure 5.9.1 Enamel sample ready for sectioning 
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When ready for sectioning, the enamel sample was mounted with greenstick compound on the 
diamond wire saw (Precision Diamond Wire Saw 3242, Well, Walter Ebner, Le Locle, Germany) as 
shown in Figure 5.9.2. 
 
Figure 5.9.2 Mounting of enamel specimen on diamond wire saw 
 
 
 
 
 
 
 
 
 
 280μm width samples were then cut perpendicular to the anatomical surface of the lesion. The 
experimental specimen usually had reduced dimensions (approx. 1mm x 3mm) compared to the 
control section so this stage of treatment was extremely complex.  Normally the sections would be 
cut longitudinally (coronal to apical), however to maximize the number of lesion obtained, the 
sections were cut transversely (Figure 5.9.3). This resulted in an increased number of samples, 
however the overall dimensions of the samples were reduced considerably (Figure 5.9.4). This made 
the subsequent polishing even more difficult. If possible 3-4 sections per sample were obtained, 
however this was dictated by the size of the sample. 
 
Figure 5.9.3 Sample cut transversely to increase number of sections 
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Figure 5.9.4 Individual enamel specimens prior to polishing 
 
 
 
 
 
 
 
 
The sectioned 280 μm slices were then attached to brass anvils (Figure 5.9.5) using nail varnish (Max 
Factor, Nailfinity, Weybridge, UK) and hand polished to sections of 80±10μm using a diamond-
impregnated disc (15µm particles, Buehler, Illinois). This utilised a series of ball bearings in sequence, 
with a gradual reduction in polishing from 250μm initially, and finishing with 80μm. To ensure 
sections were plano-parallel the sections were polished on both sides. Polished sections were then 
carefully removed from the brass anvil using acetone.  Finished sections were then submerged in 
distilled water in microtubes  until ready for TMR plate manufacture. 
 
Figure 5.9.5 Brass anvil with mounted enamel sections  
 
 
 
 
 
 
Brass Anvil 
Diamond 
impregnated disc 
49 
 
5.10 TMR plate creation 
80μm polished enamel sections were mounted on a perspex template and covered in double sided  
Scotch® tape (3M United Kingdom PLC, Berkshire, UK) as shown in Figure 5.10.1. Sections were then 
placed on a 12 step Aluminium wedge (25µm thickness) on a high resolution radiographic plate (HTA 
Enterprises, California, USA).  Radiographs where then generated by a Philips X-ray set (Philips B. V, 
Eindhoven, The Netherlands) using a copper target and nickel filter with an exposure time of 35mins 
at 20kV and 10mA at an anode to film distance of 40cm. This results in production of a stepwedge 
microradiograph as shown in Figure 5.10.2.  Exposure time required to achieve good radiographic 
contrast was based on a previous study (Lovel, 2008). 
 
Figure 5.10.1 Mounted samples on perspex template 
 
 
Figure 5.10.2 Stepwedge TMR plate 
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5.11 TMR Imaging and analysis 
The stepwedge microradiographs were then examined using a Leica Leitz DMRB optical microscope 
(Leica, Wetzlar, Germany). Enamel section images were then captured using a CCD video camera 
(Sony, Tokyo, Japan), which was connected to a computer (Hewlett Packard Pavilion t3245, USA). 
Their typical appearance is shown in Figure 5.11.1. 
 
Figure 5.11.1 Transverse microradiograph of a subsurface lesion 
                                                                 
 
 
 
Stepwedge calibration was then carried out. Although 0.999 is deemed acceptable, ideally a 
correlation of 1.00 should be achieved (Figure 5.11.2). Images where then captured using the 
software TMR 2000 v 2.0.27.16, Inspektor Research System BV, Amersterdam, The Netherlands. The 
microradiograph images were then analysed to produce a mineral content profile (Figure 5.11.3) 
using an analysis system (TMR 2006 v 3.0.0.13) using an algorithm developed by De Josselin de Jong 
(1987)  
 
Figure 5.11.2 Step wedge callibration 
 
 
 
 
 
 
 
 
 
Subsurface  Lesion 
Sound Enamel 
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Figure 5.11.3 Typical subsurface lesion mineral content profile 
 
 
 
 
 
 
 
 
 
 
 
 
5.12 Measurements 
Three main parameters were obtained from the analysis of mineral content profiles; 
• Mineral loss ΔZ (vol%μm),  
• Lesion depth Ld (μm) and  
• Lesion width Lw (μm).  
 
The difference in mineral loss or mineral gain between the control sample and the in situ sample was 
measured. From this, a percentage change in mineral loss, lesion depth and lesion width was 
calculated. This is achieved by dividing the in situ value by the control value and multiplying by 100. 
A value greater than 100 signifies further mineral loss, a value less than 100 signifies mineral gain 
and a value of 100 shows no change has occurred. The accuracy of TMR for lesion depth (Ld) is 
approximately 5 μm and mineral loss ΔZ about 200 vol%μm (Arends and Ten Bosch 1992). 
 
5.13 Statistical Analysis 
Statistical support was sought from Dr G. Burnside (Department of Biostatistics, University of 
Liverpool). Data were entered and analysed using Statistical Package for Social Sciences software 
(IBM SPSS Statistics v.22). Descriptive statistics calculations carried out included mean, standard 
deviation and percentage mineral loss group. Hypothesis testing was carried out using analysis of 
covariance (ANCOVA), adjusting for the baseline measurements, participant effect and for the order 
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in which the treatments were received. Significance level for the statistical test was set at p <0.05. A 
Pearson correlation coefficient was used to compare the quantity of Tooth Mousse™ and the 
resulting change in mineralisation. 
 
Analysis of covariance is a general linear model which blends ANOVA and regression. It is used to 
analyse if means of a dependent variable are equal for different treatment groups, while statistically 
controlling for the effects of other continuous variables. Therefore In this study it was used to 
analyse if the mineral profile means in different treatment groups were equal, whilst statistically 
controlling for baseline measurements and the order in which the treatments were received. 
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6.0 Results 
6.1 Baseline lesions 
Teeth with lesions in the range of mineral loss of 900-1700 vol%μm were selected. At this range 
shallow enamel subsurface lesions are created, which can demonstrate a significant proportional 
change in mineralisation over a short period of time. Of the 60 teeth which were demineralised, 16 
were suitable and met the criteria for use in this study, of which 15 were used.  In 10 participants 
both the experimental specimens came from the same tooth. In the other 2 participants, specimens 
from different teeth had to be used due to in situ and procedural loss. The parameters of baseline 
lesions are shown in Table 6.1.1. 
 
Table 6.1.1 Parameters of Baseline lesions selected 
Tooth number 
 Mineral Loss 
(Vol%μm) 
Lesion depth 
(μm) 
Lesion width 
(μm) 
1 1222.5 69.7 59.7 
3 1100 56.6 47.2 
4 1273.3 58.4 47.2 
6 1292.5 68.2 55.4 
7 1530 66.1 54.8 
19 1213.3 54.4 45 
20 1130 55.9 38.8 
22 1120 64.85 54.6 
25 920 48 41.3 
30 1126.6 48.1 40.8 
40 1252 63.6 50.3 
46 1140 57.3 47.6 
47 1176 57.7 44.2 
51 1090 50.2 43.8 
53 1115 62.5 52.4 
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6.2 Order of Interventions and specimens 
 
Table 6.2.1 shows the order of intervention and which specimens were used in each intervention. 
There were no drop outs from the trial. The enamel specimen placed in participant 2 was lost in situ 
during Intervention B, so an additional phase was carried out. Although the base enamel carrier was 
still in place the outer metal ring and therefore the Dacron gauze retaining the enamel sample had 
become detached. 
 
 The enamel specimen placed in participant 8 for Intervention A was damaged intra-orally during the 
in situ phase. The loss of the enamel layer resulted in an inability to carry out TMR analysis so this 
phase was also repeated at the end of the trial.  The enamel specimen of participant 6 for 
Intervention A was damaged during TMR polishing, but unfortunately this phase was unable to be 
repeated as the patient has subsequently had his fixed orthodontic appliances removed by the time 
this was identified. 
 
Table 6.2.1 Order of Interventions and specimens used in each subject 
 
Phase 1 Phase 2 Phase 3 
P
ar
ti
ci
p
an
t 
In
te
rv
en
ti
o
n
 
Sp
ec
im
en
  
In
te
rv
en
ti
o
n
 
Sp
ec
im
en
 
In
te
rv
en
ti
o
n
 
Sp
ec
im
en
 
1 B 4a A 4b     
2 B 20a A 20b B 6a 
3 B 3b A 3a     
4 A 7a B 30a     
5 A 19a B 19b     
6 B 1a A 1b Unable To  redo 
7 B 22a A 22b     
8 A 25a       B 53a A 6b 
9 A 46a B 46b     
10 B 40a A 40b     
11 A 51a B 51b     
12 A 47a B 47b     
Key 
  Lost specimen 
  Enamel specimen damaged 
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6.3. Flow Chart of clinical phase 
In total 14 orthodontic patients were approached for enrolment in the study, of which 2 patients 
declined.  All 12 participants completed the trial and therefore there were no drop-outs. A Consort 
flow diagram demonstrating the flow of participants through the trial is shown in Figure 6.3.1. 
 
6.3.1 Consort participant flow diagram 
 
 
 
 
 
 
 
 
 
 
  
Figure 6.3.2 shows a flow chart of the enamel samples used in the clinical phase. 26 enamel samples 
were used in total, with 13 in each group.  Results were obtained from 11 participants out of a 
possible 12 in Intervention A with all 12 participants in Intervention B obtaining data results. 
 
Figure 6.3.2 Flow Chart of enamel samples 
 
 
 
 
 
 
 
 
 
26 enamel samples 
Intervention A 
Control Fluoride Toothpaste 
13 enamel samples 
2 sample lost due to damage 
11 enamel samples analysed 
in total 
Intervention  B 
Tooth Mousse Paste 
13 enamel samples 
1 sample lost in situ 
12 enamel samples 
analysed in total 
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6.4 Main Results 
Raw data for baseline mineral loss, lesion depth and lesion width are shown in Appendices 4a, 4b, 
4c. Post treatment data for mineral loss, lesion depth and lesion width are shown in Appendices 5a, 
5b, 5c. The measurements were compared using analysis of covariance (ANCOVA), adjusting for the 
baseline measurements, participant effect and for the order in which the treatments were received. 
 
In order to compare the pre and post treatment  mineral loss, lesion depth and lesion width,  the 
data were normalised by dividing the sample value by the control value and multiplying by 100 
(Strang,  1987). A value of 100% mineral loss indicates no change has occurred, with values greater 
than 100 signifying further mineral loss and values less than 100 signifying mineral gain. For lesion 
depth and lesion width, values below 100 signify a decrease in lesion size and values above 100 
signify increase in lesion size (Tables 6.4.1, Table 6.4.2, and Table 6.4.3). 
 
Data was also demonstrated as percentage mineral change to aid identification of trends. Positive 
percentage mineral change (eg +10%) indicates gain in mineral and negative percentage mineral 
change (eg -10%) indicating further mineral loss.  Similarly a positive percentage change in lesion 
depth and lesion width (eg +10%) indicates a reduction in lesion size and a negative percentage 
change in lesion depth and lesion width (eg  -10%) indicating an increase in lesion size (Table 6.5.1, 
Table 6.6.1, Table 6.7.1). 
 
Table 6.4.1 Mineral loss (%) of each sample following the in situ phase  
 
 
Su
bj
ec
t
In
te
rv
en
ti
on
sp
ec
im
en
 
% mineral 
loss 
(%Volμm)
In
te
rv
en
ti
on
Sp
ec
im
en % mineral 
loss 
(%Volμm)
In
te
rv
en
ti
on
Sp
ec
im
en % mineral 
loss 
(%Volμm)
1 B 4a 81.8 A 4b 102.9
2 B 20a --------- A 20b 74.8 B 6a 71.4
3 B 3b 94.9 A 3a 101.4
4 A 7a 68.8 B 30a 102.5
5 A 19a 72.5 B 19b 67.6
6 B 1a 61.3 A 1b -------
7 B 22a 75.2 A 22b 81.5
8 A 25a     -------- B 53a 74.4 A 6b 78.1
9 A 46a 91.4 B 46b 62.9
10 B 40a 69.9 A 40b 78.0
11 A 51a 95.6 B 51b 80.5
12 A 47a 85.6 B 47b 61.7
Phase 1 Phase 2 Phase 3
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Table 6.4.2 Lesion depth (%) of each sample following  the in situ phase 
 
  
Table 6.4.3 Lesion width (%)  of each sample following the in situ phase 
 
Key 
  Lost specimen 
  Enamel specimen damaged 
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Lesion 
Depth   (%)
1 B 4a 92.5 A 4b 104.5
2 B 20a A 20b 88.2 B 6a 88.7
3 B 3b 82.3 A 3a 119.8
4 A 7a 89.5 B 30a 108.5
5 A 19a 94.9 B 19b 97.8
6 B 1a 70.4 A 1b
7 B 22a 80.0 A 22b 91.8
8 A 25a     B 53a 86.1 A 6b 87.7
9 A 46a 97.7 B 46b 91.3
10 B 40a 83.5 A 40b 88.8
11 A 51a 114.9 B 51b 101.8
12 A 47a 104.5 B 47b 84.1
Phase 1 Phase 2 Phase 3
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Lesion 
width  (%)
1 B 4a 85.4 A 4b 106.4
2 B 20a A 20b 90.2 B 6a 81.8
3 B 3b 74.6 A 3a 120.3
4 A 7a 76.9 B 30a 100.5
5 A 19a 91.6 B 19b 98.9
6 B 1a 62.6 A 1b
7 B 22a 72.0 A 22b 91.8
8 A 25a     B 53a 75.8 A 6b 83.4
9 A 46a 99.8 B 46b 84.5
10 B 40a 81.1 A 40b 93.4
11 A 51a 105.5 B 51b 86.8
12 A 47a 91.0 B 47b 90.5
Phase 1 Phase 2 Phase 3
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6.5 Mineral loss data 
Pre and post-treatment mineral loss ΔZ means and standard deviations are demonstrated in Table 
6.5.1.  Mean mineral loss ΔZ (vol%μm) reduced by 193 and 277 for treatment groups A and B 
respectively, demonstrating an increase in mineral gain and therefore remineralisation. Treatment A 
had a mean percentage mineral loss of 84.6%, therefore a + 15.4% mineral gain, with Treatment B 
having a mean percentage mineral loss of 75.4% and therefore a +24.6% mineral gain. 
 
Table 6.5.1. Mineral loss results 
Mineral loss  ΔZ (vol%μm) Treatment A  (Fluoride) Treatment B (CPP-ACP) 
Baseline mean (s.d)    1210.6  (127.3)    1172.6  (73.4) 
Post-treatment mean (s.d)    1017.6  (126)    895.6    (136.3) 
Post-treatment mean  
Adjusted (95% CI) *  
   1014.8 (927.3, 1102.4)    898.3    (810.0,985.9) 
p- value  between groups p = 0.023 
  
Mineral loss  % (s.d)       84.6       (11.7)      75.4        (12.7) 
Mineral change % (s.d)      +15.4      (11.7)    +24.6       (12.7) 
* Adjusted for order of treatment, participant effect and mineral loss at baseline 
 
Figure 6.5.2 demonstrates the percentage mineral change in both treatment groups for each 
individual participant.  This demonstrates a generalised trend of remineralisation across all 
participants in both treatment groups, with 9 of 11 participants receiving treatment A (Fluoride) and 
11 of 12 participants receiving treatment B (CPP-ACP) having positive changes in mineral gain. 
 
Figure 6.5.2 Graph of Mineral change (%) per participant 
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Null Hypothesis 
The following Null Hypotheses (Ho) were tested for mineral loss ΔZ using ANCOVA (Table 6.5.3) 
1. Mineral loss ΔZ was independent of treatment 
p=0.023      Ho is rejected 
2. Mineral loss ΔZ was independent of order 
p=0.760  Ho is not rejected 
3. Mineral loss ΔZ was independent of baseline mineral loss 
p=0.505 Ho is not rejected 
4. Mineral loss ΔZ was independent of participant effect 
p=0.138 Ho is not rejected 
 
Therefore there was no significant effect on mineral loss ΔZ for the order in which they received the 
intervention (p=0.760), participant effect (p=0.138) or for baseline mineral loss (p=0.505). However 
there was a significant effect of the treatment allocation (p=0.023). 
 
Table 6.5.3 ANCOVA table for mineral loss  
Variable Sum of 
squares 
Degrees of 
freedom 
Mean square F p-value 
Treatment 88491.01 1 88491.01 7.89 0.023 
Order 1123.18 1 1123.18 0.10 0.760 
Baseline 
mineral loss 
5461.81 1 5461.81 0.49 0.505 
Participant 
effect 
246756.19 10 24675.62 2.20 0.138 
Error 89681.75 8 11210.22   
 
6.6 Lesion depth data 
Pre and post-treatment lesion depth (Ld) means and standard deviations are demonstrated in Table 
6.6.1. Mean lesion depth reduced by 1.4μm and 5.9μm for treatment groups A and B respectively. 
This reduction in lesion depth suggests a minimal remineralising effect with treatment  A (Fluoride) 
and an increased remineralisation taking place with treatment B (CPP-ACP). Treatment A had a mean 
percentage lesion depth of 98.4%, therefore a + 1.6% reduction in depth, with treatment B having a 
mean percentage lesion depth  88.9 % and therefore an  +11.1% reduction in lesion depth. 
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Table 6.6.1. Lesion depth results 
Lesion depth Ld.  (μm) Treatment A  (Fluoride) Treatment B (CPP-ACP) 
Baseline mean (s.d)       59.7   (6.0)     58.3   (6.2) 
Post-treatment mean (s.d)       58.3   (5.1)     52.4   (3.5) 
Post-treatment mean  
Adjusted (95% CI) *  
      58.1 (54.6, 61.7)     52.7 (49.1, 56.2) 
p- value  between groups p = 0.037 
  
Lesion depth % (s.d)       98.4%    (10.7)      88.9%     (10.3) 
Lesion depth change % (s.d)      +1.6%     (10.7)     +11.1%    (10.3) 
* Adjusted for order of treatment, participant effect and baseline lesion depth 
 
Figure 6.6.2 demonstrates the lesion depth change (%) in both treatment groups for each individual 
participant.  An overall generalised trend of remineralisation was seen across most patients in both 
treatment groups; however this appears to be more pronounced in participants receiving treatment 
B (CPP-ACP).  A wide intra-subject and inter subject variation in lesion depth change was observed. 
Only 7 of 11 participants receiving treatment A had a reduction in lesion depth, whereas 10 of 12 
participants receiving treatment B had a reduction in lesion depth and therefore a remineralising 
effect. 
 
Figure 6.6.2 Graph of lesion depth change (%) per participant 
 
 
 
 
 
 
 
 
 
 
Null Hypothesis 
 
 
-20
-15
-10
-5
0
5
10
15
20
25
30
35
40
1 2 3 4 5 6 7 8 9 10 11 12
%  
change  
Participant Number 
61 
 
 
Null Hypothesis 
The following Null Hypotheses (Ho) were tested for lesion depth (Ld) using ANCOVA (Table 6.6.3) 
1. Lesion depth was independent of treatment 
p=0.037    Ho is rejected 
2. Lesion depth was independent of order  
p=0.202   Ho is not rejected 
3. Lesion depth was independent of baseline lesion depth 
p=0.125   Ho is not rejected 
4. Lesion depth was independent of participant effect 
p=0.970   Ho is not rejected 
 
Therefore there was no significant effect on lesion depth (Ld) for the order in which they received 
the intervention (p=0.202), participant effect (p=0.970) or for the baseline lesion depth (p=0.125). 
However, the intervention which they received did have a significant effect on the lesion depth 
(p=0.037). 
 
Table 6.6.3 ANCOVA table for lesion depth (Ld ) 
Variable Sum of squares Degrees of 
freedom 
Mean square F p-value 
Treatment 158.54 1 158.54 6.22 0.037 
Order 49.32 1 49.32 1.93 0.202 
Baseline lesion 
depth 
74.78 1 74.78 2.93 0.125 
Participant effect 70.05 10 7.01 0.28 0.970 
Error 204.00 8 25.50   
 
 
6.7 Lesion width data 
Pre and post-treatment lesion width (Lw) means and standard deviations are demonstrated in Table 
6.7.1. Mean lesion width reduced by 2.5μm and 7.6μm for treatment groups A and B respectively. 
This reduction in lesion width suggests a small  remineralising effect with treatment  A (Fluoride),  
and an increased remineralisation taking place with treatment B (CPP-ACP). Treatment A had a mean 
percentage lesion width of 95.5%, therefore a +4.5% reduction in width, with treatment B having a 
mean percentage  lesion width  84.7% and therefore a  +15.3% reduction in lesion width. 
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Table 6.7.1. Lesion width results 
Lesion width Lw (μm) Treatment A  (Fluoride) Treatment B (CPP-ACP) 
Baseline mean (s.d) 48.5 (6.1) 48.0 (4.7) 
Post-treatment mean (s.d) 46.0 (5.8) 40.4 (2.8) 
Post-treatment mean  
Adjusted (95% CI) *  
46.2 (43.1, 49.3) 40.3 (37.2, 43.4) 
p- value  between groups p = 0.015 
  
Lesion width % (s.d)       95.5%    (11.4)      84.7%     (8.8) 
Lesion width change % (s.d)      +4.5%     (11.4)     +15.3%      (8.8) 
* Adjusted for order of treatment, participant effect and baseline lesion width 
 
Figure 6.7.2 demonstrates the lesion width change (%) in both treatment groups for each individual 
participant. An overall generalised trend of remineralisation was seen across most participants in 
both treatment groups; however this appears to be greater in participants receiving treatment B 
(CPP-ACP). In treatment A, 7 of 11 participants had a reduction in lesion width, whereas 10 of 12 
participants receiving treatment B had a reduction in lesion depth and therefore demonstrating a 
remineralising effect. 
 
Figure 6.7.2 Graph of lesion width change (%) per participant 
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Null Hypothesis 
Null Hypothesis 
The following Null Hypotheses (Ho) were tested for lesion width (Lw) using ANCOVA (Table 6.7.3) 
1. Lesion width was independent of treatment 
p= 0.015      Ho is rejected 
2. Lesion width was independent of order  
p= 0.033 Ho is rejected 
3. Lesion width was independent of baseline lesion width 
p= 0.155 Ho is not rejected 
4. Lesion width was independent of participant effect 
p= 0.947 Ho is not rejected 
 
Table 6.7.3 ANCOVA table for Lesion width (Lw ) between subject effects 
Variable Sum of squares Degrees of 
freedom 
Mean square F p-value 
Treatment 188.91 1 188.91 9.62 0.015 
Order 129.32 1 129.32 6.59 0.033 
Baseline lesion 
width 
48.48 1 48.48 2.47 0.155 
Participant effect 65.25 10 6.53 0.33 0.947 
Error 157.05 8 19.63   
 
Therefore there was a significant effect on lesion width (Lw) for the intervention they received 
(p=0.015) and for the order in which they received the intervention (p=0.033). There was no 
significant effect on lesion width (Lw) for baseline lesion width (p=0.155) or for participant effect 
(p=0.947). 
 
Treatment order 
ANCOVA suggested that lesion width was not independent of treatment order. Participants in the 1st 
phase of treatment had a mean post treatment lesion width of 41.0μm (sd. 4.1) compared with 
45.4μm (sd.5.6) in the 2nd phase of treatment.  A hypothesis for this increased remineralisation 
effect in the 1st phase of treatment could be that participants were more compliant with the 
prescribed instructions and toothpaste usage earlier in the study. However there was no statistically 
significant difference in the quantities of fluoride toothpaste used (p=0.890) or Tooth Mousse™ used 
(p=0.678). 
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6.8 Quantity of Toothpaste and Tooth Mousse™ used  
Table 6.8.1 shows the quantity of fluoride toothpaste and Tooth Mousse™ used by each participant 
over the 4 week period. The quantity of toothpaste used ranged from 33.9g - 91.1g with an average 
mean of 74.1g used over the 4 week period. The median quantity used was 77.7 grams with an 
interquartile range of 13.1g (Figure 6.8.2).  
The mean quantity of Tooth Mousse™ used was 24.2g with a range of 18.2 g – 29.3g over the 4 week 
period. The median quantity used was 25.50g with an interquartile range of 4.0g. However there 
were 11 incomplete data sets due to failure of the participant to return the tubes, with only 73% of 
toothpaste and 83% of Tooth Mousse™ tubes being returned for analysis 
 
Table 6.8.1 Quantity of Toothpaste and Tooth Mousse™ used (g) 
Key 
    UK          Unknown as participant did not return toothpaste 
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1 B 4a 74.1 22 A 4b 70.9 -         
2 B 20a UK UK A 20b UK - B 6a 25.5 16.5 
3 B 3b 33.9 18.2 A 3a 43.3 -         
4 A 7a 70.9 - B 30a 64 25.6         
5 A 19a UK - B 19b 85 25.8         
6 B 1a 78.4 26.1 A 1b 83 -         
7 B 22a 87.6 25.5 A 22b 91.1 -         
8 A 25a   UK - B 53a 76.5 19.2 A 6b 84.4   
9 A 46a 80.8 - B 46b UK UK         
10 B 40a 87.4 26 A 40b UK -          
11 A 51a UK - B 51b UK UK         
12 A 47a 75.7 - B 47b 82.1 29.3         
     Lost specimen In situ 
  Enamel specimen damaged 
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Figure 6.8.2. Box and whisker plot of quantity of Tooth Mousse™ and fluoride toothpaste used 
demonstrating upper and lower values, median and interquartile ranges. 
 
 
 
6.9 Correlation testing for quantity of Tooth Mousse™ used 
 
Correlation Testing: Mineral loss vs quantity of Tooth Mousse™ 
A Pearson correlation coefficient can be used for parametric data to measure the strength and 
direction of a linear relationship for two continuous variables. Values range from -1.0 (a perfect 
negative relationship) to  +1.0 (a perfect positive relationship) with 0 indicating no linear 
relationship.  
 
The correlation coefficient for percentage mineral loss and quantity of Tooth Mousse™ used was 
r = - 0.488, indicating a negative correlation, however this was not statistically significant (p=0.152)  
(Figure 6.9.1). 
0
10
20
30
40
50
60
70
80
90
100
Tooth Mousse Fluoride Toothpaste
G
ra
m
s 
 
66 
 
Figure 6.9.1 Scatter plot of % mineral change  vs quantity of Tooth Mousse™ used 
 
 
Correlation Testing: Lesion depth vs quantity of Tooth Mousse™ 
The correlation of coefficient for percentage lesion depth and quantity of Tooth Mousse™ used was 
r = 0.013 (p=0.973), indicating that there is no correlation between the quantity of Tooth Mousse™ 
used and percentage lesion depth (Figure 6.9.2). 
 
Figure 6.9.2 Scatter plot of lesion depth  vs quantity of Tooth Mousse™ used 
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Correlation Testing: Lesion width vs quantity of Tooth Mousse™ 
The correlation of coefficient for percentage lesion width and quantity of Tooth Mousse™ used was  
r = 0.306 (p=0.389), indicating that there is no correlation between the quantity of Tooth Mousse™ 
used and percentage lesion width. 
 
Figure 6.9.3 Scatter plot of lesion depth  vs quantity of Tooth Mousse™ used 
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7.0. Summary 
The summarised mean, standard deviation and significance levels for the 3 main parameters for 
both treatment groups are shown in Table 7.1.1. During the in situ phase the following changes were 
observed; 
 
 An overall trend of mineral gain ΔZ, reduction in lesion depth and reduction in lesion width was 
observed in both treatment groups therefore demonstrating a remineralisation effect. All 
baseline lesions, on average remineralised during the in situ phase regardless of treatment 
group allocation, however the fluoride toothpaste combined with GC Tooth Mousse™ (CPP-ACP) 
group demonstrated an increased remineralising effect. A statistically significant reduction in 
mineral loss ΔZ (p=0.023), lesion depth (p=0.037) and lesion width (p=0.015) was observed in the 
fluoride toothpaste combined with CPP-ACP group compared with the fluoride toothpaste alone. 
  
 Mineral loss ΔZ reduction occurred in both treatment groups, with a 15.4% and 24.6% mineral 
gain in the fluoride and fluoride combined with CPP-ACP group respectively. The difference 
between these groups was statistically significant (p = 0.023). There was no significant effect on 
mineral loss ΔZ for the order in which they received the intervention (p=0.760), participant 
effect (p=0.138) or for baseline mineral loss (p=0.505). 
 
 Lesion depth (Ld) reduction occurred in both treatment groups, with a 1.6% and 11.1% reduction 
in the fluoride and fluoride combined with CPP-ACP group respectively. The difference between 
treatment groups was statistically significant (p = 0.037). There was no significant effect on 
lesion depth (Ld) for the order in which they received the intervention (p=0.202), participant 
effect (p=0.970) or for the baseline lesion depth (p=0.125). 
 
 Lesion width (Lw) reduction occurred in both treatment groups, with a 4.5% and 15.3% 
reduction in the fluoride and fluoride combined with CPP-ACP group respectively. This difference 
between treatment groups was statistically significant (p = 0.015). There was a significant effect 
on lesion width for the order in which they received the intervention (p=0.033). There was no 
significant effect on lesion width for baseline lesion width (p=0.155) or for participant effect 
(p=0.947). 
 
 A wide range of intra and inter subject data variation was noted. Mineral loss ΔZ ranged from 
2.9% mineral loss to 38.3% mineral gain. Lesion depth ranged from a 19.8% increase to a 29.6% 
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reduction in lesion depth. Lesion width ranged from 20.3% increase to a 37.4% lesion width 
reduction. 
 
 There was a large range in the quantity of fluoride toothpaste and GC Tooth Mousse™ used per 
participant over the 4 week period. The mean quantity of fluoride toothpaste used was 74.1g, 
with the lowest and highest quantities being 33.9g and 91.1g respectively. The mean quantity of 
GC Tooth Mousse™ used was 24.2g although the lowest and highest quantities used were 18.2g 
and 29.3g respectively. However there was no statistically significant correlations between the 
quantity of GC Tooth Mousse™ used and  changes in mineral loss ΔZ (p=0.152),  lesion depth 
(p=0.973) or lesion width (p=0.389).  
 
 In vitro subsurface lesion creation is often an imprecise and wasteful process. In total 60 human 
premolar teeth required demineralisation in order to produce 16 adequately demineralised 
lesions required for the study (28%). 
 
 The In situ phase of treatment was relatively successful with only 1 enamel carrier being lost, 
and 2 enamel samples being damaged during the TMR preparation process (12% total). There 
were no drop outs from the study. A total of 11 enamel samples out of a possible 12 were 
successfully analysed for the fluoride group and a complete set of data was obtained for the 
fluoride and Tooth Mousse™ group. 
 
Table 7.1.1 Summarised mean data for both treatment groups 
>100 = Mineral Loss 
<100 = Mineral Gain 
Fluoride paste 
 
Fluoride  paste + 
CPP-ACP 
Statistical Significance 
between groups 
Mineral loss ΔZ %   (sd) 84.6%   (11.7) 75.4%   (12.7) P = 0.023* 
Lesion depth  %  (sd) 98.4%    (10.7) 88.9%  (10.3) P = 0.037 * 
Lesion width  %  (sd) 
 
95.5%   (11.4 ) 84.7%   (8.8) P = 0.015 * 
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8.0 Discussion  
8.1 Discussion 
Results demonstrated an increased remineralisation effect in both treatment groups compared with 
baseline values. In most circumstances it would be expected that remineralisation would occur intra-
orally. Artificial subsurface lesions are created in vitro with a high strength demineralising gel. 
Removal from this extreme environment and placement intra-orally with a high bioavailability of 
calcium and phosphate ions is likely to cease further demineralisation and promote remineralisation, 
even in the absence of a specialised calcium and phosphate delivery system such as CPP-ACP. Lovel 
(2008) suggested that remineralisation may even take place in a distilled water solution alone. This 
in vitro study concluded that there was no statistically significant difference in remineralisation 
efficacy of GC Tooth Mousse™ compared with saliva or water. Therefore, when assessing the 
effectiveness of the addition of CPP-ACP as a remineralising agent it is important to view the results 
in comparison with the in situ fluoride group and not with the baseline parameters.  
 
The addition of CPP-ACP does seem to suggest an improved remineralisation effect compared with 
fluoride paste alone with statistically significant reductions in mineral loss ΔZ (p=0.023), lesion depth 
(p=0.037) and lesion width (p=0.015).  The addition of CPP-ACP paste resulted in a 9.2% reduction in 
mineral loss ΔZ, 9.5% reduction in lesion depth and a 10.8% reduction in lesion width compared with 
fluoride toothpaste alone. Shen et al, (2011) in a similarly designed in situ randomised controlled 
trial found comparable subsurface remineralisation results. Tooth Mousse™ (CPP-ACP) solutions 
demonstrated a statistically significant increase in remineralisation with a 24.2% percentage mineral 
gain compared to 7.9% and 16.3% for 1000ppm and 5000ppm fluoride solutions respectively. It was 
suggested that CPP–ACP containing products enhance the level of stabilised, bioavailable calcium 
and phosphate ions in saliva by a factor of 6.5 times. However Vanichvatana et al (2013) in another 
in situ study suggested that fluoride toothpaste and fluoride toothpaste combined with CPP-ACP 
yielded a 15.5% and 16.8% reduction in lesion area respectively. They concluded that the addition of 
CPP-ACP paste did not produce a statistically significant increase in remineralisation. However with 
an in situ period of only 14 days, it is possible that with an increased observation time a significant 
difference may be achieved. A recent systematic review of the literature suggested more high 
quality randomised control trials are required to establish the supplementary benefit of CPP-ACP 
application in addition to fluoride toothpaste (Li et al, 2014). 
 
In this study a large intra-participant and inter-participant variation in post-treatment changes was 
recorded.  This was particularly noted for lesion depth and lesion width changes. An explanation for 
this may be due to the fact that subsurface lesions often remineralise in an uneven or irregular 
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distribution. To minimise this, additional consideration was taken in the assessment of suitable 
subsurface lesions using QLF to ensure they appeared to be as regularly distributed at the surface as 
possible. Remineralisation traditionally occurs from the base of the lesion with continued mineral 
deposition gradually reducing the lesion depth; however this is a complex and dynamic process. Due 
to opposing fluxes of ions both mineral loss and deposition can be occurring simultaneously within 
the depth of the lesion (Ten Cate, 1990). TMR sections only assess a small area of the total lesion 
which can be at various stages of remineralisation and or demineralisation. Sectioning of the enamel 
samples after the in situ phase was extremely delicate and difficult. Any inaccuracy in producing the 
required parallel sections will alter the cross-sectional dimensions of the lesion and may alter the 
resulting mineral profile distribution. 
 
Another explanation of the large inter participant variation is the varied environmental conditions in 
which the in situ carriers were placed. Despite regular oral hygiene and dietary advice many 
orthodontic patients still have an oral environment which may support demineralisation. Increased 
quantity and frequency of cariogenic food and drinks along with poor plaque control can predispose 
in vivo enamel and also in situ enamel samples to prolonged mineral loss. Another important intra-
oral factor influencing the demineralisation process is the composition and quantity of saliva flow 
which can vary considerably, depending on the individual. In an attempt to standardise oral 
conditions, participants were given written oral hygiene instructions, detailed information of how to 
use the treatment pastes and asked not to use any additional hygiene products. Also they were 
instructed not to rinse after brushing as this can affect the retention of fluoride in the saliva and in 
the oral cavity. Despite these instructions it is possible that some participants will not have 
accurately followed the prescribed regime.  The wide range in fluoride used (33.9 - 91.1g) and GC 
Tooth Mousse™ (18.2 - 29.3g) is suggestive that some participants complied with the prescribed 
instructions to various degrees.  However this is unlikely to have impacted the results obtained as no 
statistically significant correlations were obtained between the quantity of GC Tooth Mousse™ used 
and mineral loss, lesion depth or lesion width. 
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8.2 Limitations of study 
It was not possible for the position of the enamel carriers intra-orally in the premolar region to be 
completely standardised. Not only was their placement dependent on adequate space being 
available, but also the adjacent dental and alveolar anatomy had to be taken into account to allow 
for a passive and comfortable fit.  In theory  it could be suggested that the side of the mouth the 
carrier was placed may affect the remineralisation as right-handed brushers on average tend to 
spend less time brushing the right side of their mouth and therefore have reduced plaque control 
and fluoride exposure. However, Benson (1999) found no difference in remineralisation between in 
situ enamel placed on the dominant or non-dominant side of the mouth. 
 
This study was blinded through the use of opaque insulation tape on both the regular fluoride 
toothpaste and GC Tooth Mousse™. However as these tubes were a different size and shape, this 
could have affected the standardisation required for the blinding process. Although insulation tape 
was carefully and securely placed, it could have been possible for participants to remove the tape at 
a later stage. Ideally both intervention pastes should have been in identical size and shape 
containers which were professionally concealed to ensure complete confidentiality.  
 
A major limitation of in situ studies is procedural loss. In this study 3 out of 26 enamel samples were 
lost or damaged (12%). One enamel carrier (participant 2) was lost during the in situ phase due to an 
inadequate join between the outer and inner stainless steel ring.  Although the base enamel carrier 
remained in place, the outer metal ring and therefore the Dacron gauze retaining the enamel sample 
became detached. This is a delicate procedure as over welding of this join can damage the Dacron 
gauze resulting in early detachment. There was an increased risk of this happening if the Dacron 
gauze was too dry during welding as it became very friable.  Slightly moistening and then letting dry 
at room temperature for 5 minutes aided retention of a small amount of moisture to prevent it from 
being friable but not enough moisture that it would affect the spot welding join between the two 
metals.  2 enamel samples (8%) were irreversibly damaged during the TMR preparation process. The 
sectioning and polishing of enamel samples is very intricate and delicate and as a result damage can 
easily occur. Often it is difficult to assess if the sample is damaged until TMR image capture has been 
completed. Enamel samples post treatment were sectioned transversely instead of longitudinally (as 
described in section 5.9) as this increased the number of sections obtained. However due to their 
reduced size this made handling incredibly difficult and increased the risk of damage.   The 8% loss 
due to TMR sectioning and processing in this study is favourable compared with other similar studies 
ranging from 13-22% loss (Benson, 2009;  Bryniarska, 2012). 
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An additional clinical phase was carried out when samples were lost or damaged, however this was 
not possible in one case (participant 6) as the participant had already had their fixed appliances 
removed. This resulted in one incomplete set of data for treatment A (Fluoride group). Although a 
complete set of data was obtained for treatment B (CPP-ACP group), the corresponding sample from 
participant 6 was excluded from statistical probability testing to ensure appropriate levels of 
certainty. Therefore only 11 of the 12 participants were used for the final statistical analysis, which 
may have affected the power of the study. Ideally more participants could have been recruited to 
allow for drop out and for procedural loss. However this has to be carefully balanced with justifying 
the exposure of additional orthodontic patients to the risks of an interventional trial. 
 
As the accuracy of TMR for mineral loss ΔZ is 200 vol%μm and lesion depth (Ld) is approximately 5μm 
(Arends and ten Bosch 1992), it could be suggested that lesions of increased mineral loss and lesion 
dimensions would have a reduced percentage error and therefore improved precision.  Other in situ 
TMR studies have suggested baseline subsurface lesions of mineral loss ΔZ range 2000 – 3000 
vol%μm may be more suitable in accurately quantifying remineralisation (Shen et al, 2011, Cochrane 
et al, 2008). However this may require increased in situ time to achieve an adequate change to 
demonstrate a statistically significant remineralisation effect. 
 
In this study the mean baseline parameters were mineral loss ΔZ 1180 (vol%μm), lesion depth 
58.7μm and lesion width 48.2μm. Baseline lesions in this study were of smaller dimensions and less 
mineral loss than ideally would be used, but this was limited by the difficulty in production of a large 
number of evenly demineralised high quality subsurface lesions. This was compounded by an 
inability to quantitatively analyse the mineral content profile until after destructive TMR sectioning 
took place.   
 
Every effort was taken to try to reproduce the in vivo clinical scenario of orthodontic 
demineralisation by using human premolar enamel, placed in situ in the premolar area, in 
participants receiving active orthodontic treatment. Standardisation of baseline lesions was possible 
due to the in vitro subsurface lesion creation process. Destructive TMR analysis allowed for detailed 
and accurate evaluation of the mineral changes occurring. However despite these considerations it is 
never possible in an in situ model to fully replicate the complex natural biological process of enamel 
demineralisation occurring in health living in vivo tissue.  
 
An in vivo model investigates enamel demineralisation in the natural biological oral environment and 
therefore can potentially produce highly applicable and relevant findings. However a major 
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limitation includes the inability to standardise the baseline in vivo lesion parameters and the location 
of their placement. Also the inability to utilise destructive quantitative mineral analysis techniques 
may reduce the accuracy of results obtained.   
 
8.3 Future areas for research 
The in situ study model is an effective method of quantitatively analysing the demineralisation and 
remineralisation process.  Further in situ research should utilise baseline lesion of larger dimensions 
and increased mineral loss ΔZ 1500-2000 vol%μm as this may minimise the relative effect of 
measurement error.  Recent research demonstrating the effectiveness of high concentration fluoride 
toothpastes (Sonesson et al 2014) would propose that future trials should involve the comparison of 
3 intervention arms; regular fluoride (1450ppm), high concentration fluoride (5000ppm) and CPP-
ACP paste. 
 
More in vivo research may also be beneficial as this can accurately replicate the complex and 
dynamic demineralisation process. As non-destructive quantitative analysis is required for such 
studies, QLF is suggested as the most appropriate method of identifying, analysing and monitoring 
the demineralisation process. QLF could be used to identify and quantify patients with white spot 
lesion prior to and during orthodontic treatment. Those with white spot lesions could be randomly 
allocated to one of the remineralising treatment groups, to allow for in vivo comparison of 
remineralising effectiveness. 
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9.0 Conclusions 
In this study the null hypothesis that there was no difference between the remineralising potential 
abilities of GC Tooth Mousse™ and fluoride toothpaste in orthodontic patients was rejected. Despite 
a wide range in intra-participant and inter-participant data, an overall trend of remineralisation was 
observed in both treatment groups as demonstrated by reduction in mineral loss ΔZ, reduction in 
lesion depth and reduction in lesion width. On average, all baseline lesions remineralised during the 
in-situ phase regardless of treatment group allocation, however the fluoride toothpaste combined 
with GC Tooth Mousse™ (CPP-ACP) group demonstrated an increased remineralising effect. A 
statistically significant reduction in mineral loss ΔZ (p=0.023), lesion depth (p=0.037) and lesion 
width (p=0.015) was observed in the fluoride toothpaste combined with CPP-ACP group compared 
to the fluoride toothpaste alone. 
 
This study suggests that the application of GC Tooth Mousse™ in addition to regular fluoride paste 
does have an increasing remineralisation effect on subsurface enamel lesions in orthodontic 
patients.  
 
9.1 Implications 
Enamel demineralisation is a common adverse side effect of orthodontic treatment. The use of 
toothpastes containing CPP-ACP such as GC Tooth Mousse™ has been shown to reduce this 
demineralisation process and promote remineralisation. CPP-ACP pastes in combination with regular 
fluoride toothpaste should be recommended for patients undergoing orthodontic treatment who 
are at high risk of demineralisation or who have demonstrated early signs of white spot lesion 
formation. CPP-ACP paste may also be useful for patients after fixed appliances to promote 
remineralisation of areas where orthodontic demineralisation is evident. 
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11.0 Appendices 
 
Appendix 1. Participant instruction sheets 
         
Appendix 1a  
 
 
 
 
 
 
Instructions for Toothpaste A 
 
Brush your teeth with the toothbrush and toothpaste A  provided.  
Use a pea-sized amount of toothpaste and brush for two minutes. 
Do not rinse your mouth, spit out the excess if you wish. 
Brush your teeth twice a day. 
Do not use any other mouth rinses or toothpastes. 
 
 
 
 
 
 
 
 
 
 
Participant Instruction Sheets 
 
 
Title of Research Project: 
   
An in situ study to determine the effects of  calcium based toothpastes 
in orthodontic patients 
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Appendix 1b 
 
 
 
 
 
 
Instructions for Toothpaste A  + Paste B  
 
Brush your teeth with the toothbrush and toothpaste A  provided.  
Use a pea-sized amount of toothpaste and brush for two minutes. 
Do not rinse your mouth, spit out the excess if you wish. 
 
Take a pea-sized amount of paste B  
Wipe this across your teeth, including the carrier. 
Leave on the tooth surface undisturbed for a minimum of 3 minutes 
Then use your tongue to spread the paste throughout the mouth.  
 
Hold in the mouth for a further 1-2 minutes 
 
Spit out thoroughly but avoid rinsing 
 
Clean your teeth in this way twice a day. 
Do not use any other mouth rinses or toothpastes. 
 
 
 
 
Participant Instruction Sheets 
 
 
Title of Research Project: 
   
An in situ study to determine the effects of  calcium based toothpastes 
in orthodontic patients 
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Appendix 2. Participant information sheets 
 
Appendix 2a 
 
 
 
 
Department of clinical Dental Sciences 
Liverpool University Dental Hospital and School of Dentistry 
Pembroke Place L3 5PS 
 
 
PARENT/ LEGAL GUARDIAN INFORMATION SHEET 
 
 
An in situ study to determine the effects of calcium based toothpastes in orthodontic 
patients 
 
 
 
What is the purpose of the study? 
During fixed brace treatment teeth are susceptible to loss of mineral which may appear as white or 
brown marks on the teeth. This is due to plaque accumulating on the teeth around the brace where 
effective tooth brushing is more difficult. Fluoride toothpastes are recommended to prevent the 
occurrence of these white spots. Calcium based toothpastes are now available and have been shown 
in some studies to be more effective at preventing this tooth damage. The purpose of this study is to 
find out if calcium based toothpastes in combination with fluoride toothpastes are more effective than 
regular fluoride toothpastes alone. 
 
An in situ study is a study where the participants are the carrier for a specimen of enamel which has 
previously been treated to mimic a white spot on a tooth. This allows us to study the effectiveness of 
toothpastes on a particular specimen of enamel that has previously been sterilised. 
 
A Cross-over study is where each participant has the opportunity to use both toothpastes in turn. 
There is a rest period between treatments so that one toothpaste can not affect the result of the other 
toothpaste being tested. 
 
Has this study been approved? 
Yes. Liverpool Local Research Ethics Committee has given approval for this study. 
 
Who is paying for the study? 
The School of Dental Sciences is paying for the study. The Royal Liverpool and Broadgreen 
University Hospital Trust and the University of Liverpool are co-sponsoring the study. 
 
Who will be conducting the study? 
The study is being run by Prof. Susan Higham (Professor in Oral Microbiology), Dr Norah 
Flannigan (Senior Clinical Lecturer in Orthodontic) and Mr Andrew Garry (Specialist Registrar in 
Orthodontics). 
 
Why has my child been asked to take part? 
Your child had been asked to take part because they are undergoing orthodontic treatment 
with fixed braces on their teeth 
 
 
What will I have to do? 
During a routine brace appointment a small carrier containing a piece of sterilised human 
enamel will be attached to the wire part of the brace, positioned towards the back part of the lower 
86 
 
brace (Figure 1 ). This will not affect how the brace works. Your child will be given a toothbrush and 
either one or two toothpastes and given instructions on their use.. 4 weeks later at the next 
orthodontic appointment the carrier will be removed from the brace and sent to the laboratory for 
analysis. The brace will be adjusted as usual. Your child will then be instructed to use a standard 
fluoride toothpaste for the next 4 weeks with no carrier on the brace. At the next 4 week appointment 
a new carrier will be attached to the brace and your child will be given another paste/pastes to use. At 
the next orthodontic appointment in 4 weeks the second carrier will be removed and the trial will be 
finished 
 
Your child will have in total 2 carriers attached to your brace with 2 different types of 
toothpastes to use. One of the regimes will involve brushing with a pea-sized amount of fluoride 
toothpaste for 2 minutes twice a day. The other regime will involve brushing with a pea-sized amount 
of fluoride toothpaste for 2 minutes twice a day in addition to a calcium-based toothpaste being 
applied to the teeth for 5 minutes twice a day. 
  
Your child will be asked not to use any other type of toothpaste or mouth rinse during the trial. 
 
Figure 1. Example of carrier attached to lower brace 
 
 
How long will the study last? 
The study will last for approximately 4 months of your child's treatment. 
 
What if I don’t want to take part? 
Your child’s treatment will continue as normal. You should not feel obliged to take part and 
you do not have to give a reason if you don’t want to. If you do take part, but decide later that you 
don’t want to continue you can withdraw at any time without giving a reason. 
 
What if you have a question or there is a problem on the study? 
If you have a concern about any aspect of this study, you should speak to the researchers 
who will do their best to answer any questions on 0151 706 5210. If you remain unhappy and wish to 
complain formally, you can do this through the Patient Advice Liaison service on 0151 706 3216   or 
by emailing; complaints@rlbuht.nhs.uk. Details can be obtained from 
http://www.rlbuht.nhs.uk/for_patients/Complaints_FAQs.asp  
.  
How will my child’s data be collected and managed? 
All information about your child will be anonymous. As soon as we have collected the 
necessary data all information which identifies your child will be removed and replaced by a code 
number. The data will be processed and analysed by the research staff of the study. The person 
responsible for security and access to your data is Dr Norah Flannigan, chief investigator of the study. 
Data will be stored for 10 years in compliance with hospital policy. 
 
What do I do if I would like my child to take part? 
If you would like your child to take part, please sign the relevant sections of the consent form 
that you have been provided with. 
 
 
Thank you for taking the time to read this 
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Appendix 2b 
 
 
 
 
Department of clinical Dental Sciences 
Liverpool University Dental Hospital and School of Dentistry 
Pembroke Place L3 5PS  
 
 
 
  CHILD INFORMATION SHEET 
 
 
An in situ study to determine the effects of calcium based toothpastes in orthodontic 
patients 
 
 
 
What is the purpose of the study? 
During fixed brace treatment teeth are susceptible to tooth damage which may appear as 
white or brown marks on the teeth. Fluoride toothpastes are recommended to prevent the occurrence 
of these white spots. Calcium based toothpastes are now available and have been shown in some 
studies to be more effective at preventing this tooth damage. The purpose of this study is to find out if 
calcium based toothpastes in combination with fluoride toothpastes are more effective than regular 
fluoride toothpastes alone. 
 
In this study a small section of sterilised tooth is attached to the brace to study the 
effectiveness of different toothpastes. Both toothpastes will be used in turn, with a rest period 
between treatments so that one toothpaste can not affect the result of the other toothpaste being 
tested. 
 
Has this study been approved? 
Yes. Liverpool Local Research Ethics Committee has given approval for this study. 
 
Who is paying for the study? 
The School of Dental Sciences is paying for the study. The Royal Liverpool and Broadgreen 
University Hospital Trust and the University of Liverpool are co-sponsoring the study 
 
Who will be conducting the study? 
The study is being run by Prof. Susan Higham (Professor in Oral Microbiology), Dr Norah 
Flannigan (Senior Clinical Lecturer in Orthodontics) and Mr Andrew Garry (Specialist Registrar in 
Orthodontics). 
 
Why have I been asked to take part? 
You have been asked to take part because you are undergoing orthodontic treatment with 
fixed braces on your teeth. 
 
 
What will I have to do? 
During your routine brace appointment a small carrier containing a piece of sterilised human 
tooth will be attached to the wire part of your brace, positioned towards the back part of your lower 
brace (Figure 1). This will not affect how your brace works. You will be given a toothbrush and either 
one or two toothpastes and given instructions on their use. 4 weeks later at your next orthodontic 
appointment the carrier will be removed from your brace and sent to the laboratory for analysis. Your 
brace will be adjusted as usual. You will then be instructed to use a standard fluoride toothpaste for 
the next 4 weeks with no carrier on your brace. At your next 4 week appointment a new carrier will be 
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attached to the brace and you will be given another paste/pastes to use. At the next orthodontic 
appointment in 4 weeks the second carrier will be removed and the trial will be finished. 
 
You will have in total 2 carriers attached to your brace with 2 different types of toothpastes to 
use. One of the regimes will involve brushing with a pea-sized amount of fluoride toothpaste for 2 
minutes twice a day. The other regime will involve brushing with a pea-sized amount of fluoride 
toothpaste for 2 minutes twice a day in addition to a calcium-based toothpaste being applied to the 
teeth for 5 minutes twice a day. 
 
You will be asked not to use any other type of toothpaste or mouth rinse during the trial. 
 
Fig.1. Example of carrier attached to lower brace 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How long will the study last? 
The study will last for approximately 4  months of your treatment 
 
What if I don’t want to take part? 
Your treatment will continue as normal. You should not feel obliged to take part and you do 
not have to give a reason if you don’t want to. If you do take part, but decide later that you don’t want 
to continue you can withdraw at any time without giving a reason. 
 
What if you have a question or there is a problem on the study? 
If you have a concern about any aspect of this study, you should speak to the researchers 
who will do their best to answer any questions on 0151 706 5210. If you remain unhappy and wish to 
complain formally, you can do this through the Patient Advice Liaison service on 0151 706 3216   or 
by emailing; complaints@rlbuht.nhs.uk. Details can be obtained from 
http://www.rlbuht.nhs.uk/for_patients/Complaints_FAQs.asp  
 
How will my data be collected and managed? 
All information about you will be anonymous. As soon as we have collected the necessary 
data all information which identifies you will be removed and replaced by a code number. The data 
will be processed and analysed by the research staff of the study. The person responsible for security 
and access to your data is Dr Norah Flannigan, chief investigator of the study. Data will be stored for 
10 years in compliance with hospital policy. 
 
What do I do if I would like to take part? 
If you would like to take part, please sign the relevant sections of the consent form that you 
have been provided with. 
 
 
Thank you for taking the time to read this 
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Appendix 3. Consent forms 
 
Appendix 3a 
 
 
 
 
CHILD ASSENT FORM  
Centre Number: 
 
Study Number: 
 
Participant Identification Number: 
 
          
     Name of Participant                                               Date                   Signature 
 
 
 
                 
     Name of Person taking consent                         Date                  Signature 
 
The contact details of lead Researcher are: 
Dr Norah Flannigan 
Orthodontic Department, Liverpool Dental Hospital,  
0151 706 5210 
nlf@liverpool.ac.uk 
 
Title of Research Project:   
An in situ study to determine the effects of  calcium based toothpastes in 
orthodontic patients. 
 
   
 
 
 
Please 
initial 
box 
Researcher: Andrew Garry  
1. I confirm that I have read and have understood the information sheet dated 16
th
 
September 2013 (Version 1.2) for the above study. I have had the opportunity 
to consider the information, ask questions and have had these answered 
satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my rights being affected.   
 
 
 
3. I understand that my medical records may be looked at by regulatory 
authorities or by persons from the Trust where it is relevant to my taking part in 
this research. I give permission for these individuals to access this information  
 
 
 
4. I understand that the data collected during the study will be analysed by the 
study investigators. I give permission for these individulas to have access to my 
records. 
 
 
 
5. I agree to take part in the above study.    
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Appendix 3b 
 
 
 
 
 
PARENT/ LEGAL GUARDIAN CONSENT FORM  
Centre Number: 
 
Study Number: 
 
Participant Identification Number: 
 
          
     Parent/ Legal Guardian                                      Date                   Signature 
 
 
 
                 
     Name of Person taking consent                         Date                  Signature 
 
The contact details of lead Researcher are: 
Dr Norah Flannigan 
Orthodontic Department, Liverpool Dental Hospital,  
01517065210 
nlf@liverpool.ac.uk 
Title of Research Project:   
An in situ study to determine the effects of calcium based toothpastes in 
orthodontic patients. 
 
   
 
 
 
Please 
initial 
box 
Researcher : Andrew Garry  
1. I confirm that I have read and have understood the information sheet dated 
16
th
 December 2013 (Version 1.2) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
 
 
2. I understand that my child’s participation is voluntary and that I am free to 
withdraw my child at any time without giving any reason, without my rights 
being affected.   
3. I understand that my child’s medical records may be looked at by 
regulatory authorities or by persons from the Trust where it is relevant to 
my child taking part in this research. I give permission for these individuals 
to access this information  
 
 
 
 
 
4. I understand that the data collected during the study will be analysed by the 
study investigators. I give permission for these individulas to have access 
to my child records. 
 
5. I agree for my child to take part in the above study.    
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Appendix 3c 
 
 
 
 
 
PARENT/ LEGAL GUARDIAN CONSENT FORM  
Centre Number: 
 
Study Number: 
 
Participant Identification Number: 
 
 
          
     Parent/ Legal Guardian                                      Date                   Signature 
 
 
 
                 
     Name of Person taking consent                         Date                  Signature 
 
The contact details of lead Researcher are: 
Dr Norah Flannigan 
Orthodontic Department, Liverpool Dental Hospital,  
01517065210 
nlf@liverpool.ac.uk 
 
Title of Research Project:   
An in situ study to determine the effects of calcium based toothpastes in 
orthodontic patients. 
 
   
 
 
 
Please 
initial 
box 
Researcher : Andrew Garry  
6. I confirm that I have read and have understood the information sheet dated 16
th
 
December 2013 (Version 1.2) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
 
7. I understand that my child’s participation is voluntary and that I am free to 
withdraw my child at any time without giving any reason, without my rights 
being affected.   
8. I understand that my child’s medical records may be looked at by regulatory 
authorities or by persons from the Trust where it is relevant to my child taking 
part in this research. I give permission for these individuals to access this 
information  
 
 
 
 
 
9. I understand that the data collected during the study will be analysed by the 
study investigators. I give permission for these individulas to have access to my 
child records. 
 
10. I agree for my child to take part in the above study.    
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Appendix 4. Baseline raw data 
 
Appendix 4a  
Raw data for baseline mineral loss (%Volμm) 
 
 
 
 
 
Appendix 4b  
Raw data for baseline lesion depth (μm) 
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1 B 4a 1273 A 4b 1273.0
2 B 20a A 20b 1130.0 B 6a 1292.0
3 B 3b 1100.0 A 3a 1100.0
4 A 7a 1530.0 B 30a 1126.0
5 A 19a 1213.0 B 19b 1213.0
6 B 1a 1223.0 A 1b
7 B 22a 1120.0 A 22b 1120.0
8 A 25a     B 53a 1115.0 A 6b 1293.0
9 A 46a 1140.0 B 46b 1140.0
10 B 40a 1252.0 A 40b 1252.0
11 A 51a 1090.0 B 51b 1090.0
12 A 47a 1176.0 B 47b 1176.0
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2 B 20a A 20b 55.9 B 6a 68.2
3 B 3b 56.6 A 3a 56.6
4 A 7a 69.5 B 30a 48.0
5 A 19a 54.4 B 19b 54.4
6 B 1a 69.7 A 1b
7 B 22a 64.9 A 22b 64.9
8 A 25a     B 53a 62.5 A 6b 68.2
9 A 46a 57.3 B 46b 57.3
10 B 40a 63.6 A 40b 63.6
11 A 51a 56.2 B 51b 56.2
12 A 47a 57.7 B 47b 57.7
Phase 1 Phase 2 Phase 3
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Appendix 4c  
Raw data for baseline lesion width (μm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5. Post treatment raw data 
 
Appendix 5a  
Raw data for post treatment mineral loss (%Volμm) 
 
 
 
 
 
Su
bj
ec
t
In
te
rv
en
ti
on
sp
ec
im
en
 End 
mineral 
loss 
(%Volμm) In
te
rv
en
ti
on
Sp
ec
im
en End mineral 
loss 
(%Volμm)
In
te
rv
en
ti
on
Sp
ec
im
en End mineral 
loss 
(%Volμm)
1 B 4a 1042 A 4b 1310.0
2 B 20a A 20b 845.0 B 6a 923.0
3 B 3b 1044.0 A 3a 1115.0
4 A 7a 1053.0 B 30a 1155.0
5 A 19a 880.0 B 19b 820.0
6 B 1a 750.0 A 1b
7 B 22a 843.0 A 22b 913.0
8 A 25a     B 53a 830.0 A 6b 1010.0
9 A 46a 1042.0 B 46b 716.0
10 B 40a 875.0 A 40b 976.6
11 A 51a 104.2 B 51b 877.0
12 A 47a 1006.6 B 47b 726.0
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2 B 20a A 20b 38.8 B 6a 55.4
3 B 3b 47.2 A 3a 47.2
4 A 7a 59.8 B 30a 40.8
5 A 19a 45.0 B 19b 45.0
6 B 1a 59.7 A 1b
7 B 22a 54.6 A 22b 54.6
8 A 25a     B 53a 52.4 A 6b 55.4
9 A 46a 47.6 B 46b 47.6
10 B 40a 50.3 A 40b 50.3
11 A 51a 43.8 B 51b 43.8
12 A 47a 44.2 B 47b 44.2
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Appendix 5b  
Raw data for post treatment lesion depth (μm) 
 
 
 
 
 
Appendix 5c  
Raw data for post treatment lesion width (μm) 
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4 A 7a 62.2 B 30a 52.2
5 A 19a 51.6 B 19b 53.2
6 B 1a 49.1 A 1b
7 B 22a 51.9 A 22b 59.5
8 A 25a     B 53a 53.8 A 6b 59.8
9 A 46a 56.0 B 46b 52.3
10 B 40a 53.1 A 40b 56.5
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4 A 7a 46.0 B 30a 41.0
5 A 19a 41.2 B 19b 44.5
6 B 1a 37.4 A 1b
7 B 22a 39.3 A 22b 50.1
8 A 25a     B 53a 39.7 A 6b 46.2
9 A 46a 47.5 B 46b 40.2
10 B 40a 40.8 A 40b 47.0
11 A 51a 46.2 B 51b 38.0
12 A 47a 40.2 B 47b 40.0
Phase 1 Phase 2 Phase 3
